🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

◆

Subtypes

3

Severe early-onset

Presents in infancy with encephalopathy, Leigh syndrome features on MRI, seizures, severe hypotonia, and rapid neurological deterioration. Often fatal in infancy to early childhood (deaths at 10.5 months to ~6 years reported). Associated with more damaging FDXR variants. Deaths from progressive neurological decline, respiratory failure, or complications of Leigh syndrome.

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"Mortality is high, with 18% of patients, often infants, passing from complications. "

Documents the severe early-onset infantile lethality subset of the FDXR-related mitochondriopathy spectrum.

Classic childhood-onset

Presents in early childhood with progressive optic atrophy, auditory neuropathy, developmental delay, ataxia, and peripheral neuropathy. Most common presentation.

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"Optic atrophy, movement disorder, and developmental delay were frequent findings. "

The Campbell 2024 natural history study documents the most common presentation of FDXR-related mitochondriopathy characterized by optic atrophy and developmental delay.

Mild late-onset

Later onset with progressive optic atrophy and auditory neuropathy as predominant features. Slower progression, survival into second decade and beyond (patients up to age 20 documented). Associated with variants retaining residual FDXR function.

Show evidence (1 reference)

PMID:29040572 SUPPORT Human Clinical

"As is common for mitochondrion-related diseases, patients presented with variable clinical phenotypes, consistent with mitochondriopathy. "

Peng et al. document the clinical variability of FDXR mitochondriopathy across 13 unrelated families, including older surviving individuals (Table 1, patient aged 20 yrs).

⚙

Pathophysiology

10

FDXR Deficiency and Iron-Sulfur Cluster Assembly Impairment

Biallelic FDXR mutations cause reduced ferredoxin reductase activity, impairing electron transfer from NADPH to ferredoxins FDX1 and FDX2. This disrupts iron-sulfur cluster assembly, a critical pathway for mitochondrial function. FDXR protein has an N-terminal mitochondrial targeting peptide and contains FAD (flavin adenine dinucleotide) and NADPH binding domains. Missense variants disrupt electron transfer capacity or protein stability. Complete FDXR loss is likely lethal across species.

Neuron link

FDXR link

Iron-Sulfur Cluster Assembly link ↓ DECREASED Intracellular Iron Ion Homeostasis link ↕ DYSREGULATED

Downstream

Mitochondrial Respiratory Chain Dysfunction

Impaired Mitochondrial Steroidogenesis

Failure to Thrive Systemic mitochondrial dysfunction from FDXR deficiency is associated with failure to thrive in the FDXR-related disorder spectrum.

Show evidence (1 reference)

PMID:29040572 SUPPORT In Vitro

"In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). "

Fibroblast assays demonstrating impaired electron transfer and mitochondrial dysfunction from FDXR mutations.

Impaired Mitochondrial Steroidogenesis

FDXR also transfers electrons to mitochondrial cytochrome P450 enzymes required for steroid hormone biosynthesis. FDXR dysfunction can therefore impair steroidogenesis and contribute to adrenal insufficiency in severe early-onset disease.

Steroid Biosynthetic Process link ↓ DECREASED

Downstream

Adrenal Insufficiency

Mitochondrial Respiratory Chain Dysfunction

FDXR deficiency leads to reduced activity of mitochondrial complexes I, II, III, and IV due to impaired iron-sulfur cluster incorporation into respiratory chain components. This causes decreased ATP production and increased ROS.

Electron Transport Chain link ↓ DECREASED

Downstream

Mitochondrial Iron Overload

Neurodegeneration

Neuroinflammation

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"The deficiencies of complex I in the brain, heart, and muscle tissues of the FdxrR389Q/R389Q mutants were all significantly recovered after the AAV treatment "

Demonstrates that Fdxr mutation causes mitochondrial complex deficiencies that can be reversed with gene therapy.

Mitochondrial Iron Overload

Loss of FDXR function causes iron accumulation in mitochondria due to impaired iron-sulfur cluster synthesis. Mitochondrial iron overload accelerates ROS production and enhances oxidative stress, contributing to cellular damage.

Intracellular Iron Ion Homeostasis link ↕ DYSREGULATED

Downstream

Ferroptosis via NRF2 Pathway Disruption

Neurodegeneration

Neuroinflammation

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"the FdxrR389Q/R389Q mutants re-acquired iron homeostasis in heart and muscle after AAV treatment "

Demonstrates mitochondrial iron overload in Fdxr mutant mice that is reversed by gene therapy.

Ferroptosis via NRF2 Pathway Disruption

Mitochondrial iron overload from FDXR deficiency increases lipid peroxidation in inner mitochondrial and plasma membranes, leading to ferroptotic cell death. Disruption of the NRF2 pathway and its target gene SLC7A11 plays a key role in this pathogenic process. NRF2 activation with omaveloxolone mitigates pathogenesis in preclinical models, suggesting ferroptosis as a tractable therapeutic target.

Lipid Oxidation link ↑ INCREASED Response to Oxidative Stress link ↑ INCREASED

Downstream

Neurodegeneration

Show evidence (1 reference)

DOI:10.1038/s41420-025-02840-y SUPPORT Model Organism

"We demonstrated increased lipid peroxidation in the inner mitochondrial and plasma membranes, resulting in susceptibility to ferroptosis. Closer examination revealed that disruption of the NRF2 pathway and its target gene SLC7A11 appear to play important roles in this pathogenic process. "

Mouse model and cell studies demonstrate ferroptosis as a novel pathogenic mechanism in FDXR-related disease via NRF2/SLC7A11 disruption.

Neurodegeneration

FDXR mutations cause progressive neurodegeneration with Fluoro-Jade C positivity in cerebellum, cerebral cortex, and hippocampus. Neuronal loss is the primary driver of clinical features including optic atrophy, ataxia, and neuropathy. FDXR deficiency may also destabilize p53/TP73, contributing to impaired apoptotic regulation and potential spontaneous tumor susceptibility as demonstrated in the mouse model.

Neuron link

Apoptotic Process link ↑ INCREASED

Downstream

Optic Atrophy and Visual Loss

Peripheral Neuropathy and Demyelination

Auditory Neuropathy Auditory neuropathy is a common clinical manifestation within the FDXR neurodegenerative mitochondriopathy spectrum.

Ataxia Ataxia is a frequent neurologic manifestation of the FDXR neurodegenerative disease spectrum.

Developmental Delay Developmental delay is a frequent neurodevelopmental manifestation of FDXR-related mitochondrial dysfunction.

Developmental Regression Developmental regression is a distinct neurodevelopmental manifestation within the FDXR-related disorder spectrum.

Movement Disorder Movement disorder is a frequent neurologic manifestation of the same FDXR disease spectrum.

Hypotonia Global hypotonia is part of the common neurologic presentation of FDXR-related disease.

Seizures Seizures can accompany the neurologic FDXR disease presentation.

Leigh Syndrome Features on MRI Severe FDXR-related mitochondrial disease can present with Leigh syndrome and severe infantile encephalopathy.

Spasticity Spasticity occurs within the FDXR neurodegenerative mitochondriopathy spectrum.

Microcephaly Microcephaly is part of the reported FDXR-related neurodevelopmental phenotype spectrum.

Feeding Difficulty Severe infantile FDXR-related disease can include impaired feeding in the setting of broader neurologic and systemic involvement.

Show evidence (1 reference)

PMID:30250212 SUPPORT Human Clinical

"we expand upon those results by describing two new cases of disease-causing FDXR variants in patients with variable severity of phenotypes, including evidence of an inflammatory response in brain autopsy "

Describes neurodegeneration in FDXR patients with brain autopsy findings and mouse model showing Fluoro-Jade C positivity.

Neuroinflammation

FDXR-related neurodegeneration is accompanied by reactive gliosis with increased GFAP-positive astrocytes. Brain autopsy and mouse model show astrogliosis in cerebellum, cerebral cortex, and hippocampus, indicating a secondary inflammatory response to neuronal injury.

Astrocyte link

Inflammatory Response link ↑ INCREASED

Show evidence (1 reference)

PMID:30250212 SUPPORT Human Clinical

"we expand upon those results by describing two new cases of disease-causing FDXR variants in patients with variable severity of phenotypes, including evidence of an inflammatory response in brain autopsy "

Documents neuroinflammation with astrogliosis in FDXR patient brain autopsy and increased GFAP in mouse model.

Optic Atrophy and Visual Loss

Progressive optic nerve atrophy with loss of retinal ganglion cells. Present in approximately 93% of patients. Leads to progressive visual loss, often to legal blindness. Retinal dystrophy with attenuated vessels and retinal vascular occlusion may also occur as distinct clinical characteristics.

Retinal ganglion cell link

Apoptotic Process link ↑ INCREASED

Downstream

Optic Atrophy Retinal ganglion cell and optic nerve involvement manifests clinically as optic atrophy and progressive visual loss.

Retinal Dystrophy Retinal dystrophy is an ocular manifestation reported alongside optic atrophy in FDXR-associated disease.

Nystagmus Nystagmus is an ocular manifestation reported with FDXR-related optic atrophy and retinal disease.

Strabismus Strabismus is another ocular manifestation reported in the FDXR-related ocular phenotype spectrum.

Show evidence (1 reference)

PMID:37481223 SUPPORT Human Clinical

"all patients presented with retinal dystrophy, and electroretinogram showed severely impaired cone and rod functions in their first decades "

Documents retinal dystrophy and vascular abnormalities in FDXR patients.

Peripheral Neuropathy and Demyelination

Sensorimotor peripheral neuropathy with demyelination of sciatic and other peripheral nerves. Present in ~23% of patients. Contributes to ataxia, hypotonia, and motor disability.

Schwann cell link

Downstream

Peripheral Neuropathy

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"The review of clinical findings in previously described cases from literature reveals also a significant incidence of sensorimotor peripheral polyneuropathy (22.72%) and ataxia (43.18%) "

Systematic review documenting frequency of peripheral neuropathy and ataxia in FDXR patients.

Acute-Onset Peripheral Neuropathy

Some patients present with acute or subacute onset of peripheral neuropathy that can mimic inflammatory neuropathy. Only in later stages do typical features of FDXR-associated disease become apparent. Intercurrent infections may trigger acute neurological deterioration, as compromised mitochondria cannot meet increased metabolic demands during febrile stress.

Downstream

Peripheral Neuropathy

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"Both patients presented with an acute-sub-acute onset of peripheral neuropathy and only in later stages of the disease developed the typical features of FDXR-associated disease "

Describes acute-onset neuropathy presentation that can mimic inflammatory peripheral neuropathy.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

18

Digestive 1

Feeding Difficulty Feeding difficulties (HP:0011968)

Show evidence (1 reference)

PMID:30250212 SUPPORT Human Clinical

"She then spent 2.5 months in neonatal intensive care unit for poor feeding, abdominal distension, and initial respiratory distress syndrome. "

The case description documents poor feeding in a severely affected infant with biallelic FDXR variants.

Ear 1

Auditory Neuropathy FREQUENT Sensorineural hearing impairment (HP:0000407)

Endocrine 1

Adrenal Insufficiency OCCASIONAL Adrenal insufficiency (HP:0000846)

Eye 4

Optic Atrophy VERY_FREQUENT Optic atrophy (HP:0000648)

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"Optic atrophy, movement disorder, and developmental delay were frequent findings. "

Optic atrophy identified as one of the most frequent findings in the natural history study.

Nystagmus OCCASIONAL Nystagmus (HP:0000639)

Show evidence (1 reference)

ORPHA:543470 SUPPORT Other

"HP:0000639 | Nystagmus | Occasional (29-5%)"

Orphanet records nystagmus as an occasional phenotype.

Retinal Dystrophy FREQUENT Retinal dystrophy (HP:0000556)

Show evidence (1 reference)

PMID:37481223 SUPPORT Human Clinical

"Retinal dystrophy with attenuated retinal vessels appearing as white lines was observed in this cohort, and the FFA images revealed that retinal vascular occlusion could be a distinct clinical characteristic "

Documents retinal dystrophy with characteristic vascular findings.

Strabismus Strabismus (HP:0000486)

Show evidence (1 reference)

PMID:39746537 SUPPORT Human Clinical

"Our review of the existing literature reveals other common ocular findings of myopia, nystagmus, strabismus, retinal dystrophy, attenuation of retinal vessels, and cataracts. "

The review reports strabismus among ocular manifestations of FDXR-related disorder.

Head and Neck 1

Microcephaly OCCASIONAL Microcephaly (HP:0000252)

Show evidence (1 reference)

ORPHA:543470 SUPPORT Other

"HP:0000252 | Microcephaly | Occasional (29-5%)"

Orphanet records microcephaly as an occasional phenotype.

Musculoskeletal 2

Hypotonia FREQUENT Hypotonia (HP:0001252)

Spasticity FREQUENT Spasticity (HP:0001257)

Show evidence (1 reference)

ORPHA:543470 SUPPORT Other

"HP:0001257 | Spasticity | Frequent (79-30%)"

Orphanet records spasticity as a frequent phenotype.

Nervous System 7

Ataxia FREQUENT Ataxia (HP:0001251)

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"The review of clinical findings in previously described cases from literature reveals also a significant incidence of sensorimotor peripheral polyneuropathy (22.72%) and ataxia (43.18%) "

Systematic review documenting 43% frequency of ataxia.

Seizures OCCASIONAL Seizure (HP:0001250)

Developmental Delay FREQUENT Global developmental delay (HP:0001263)

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"Optic atrophy, movement disorder, and developmental delay were frequent findings. "

Developmental delay identified as a frequent finding in natural history study.

Developmental Regression FREQUENT Developmental regression (HP:0002376)

Show evidence (1 reference)

ORPHA:543470 SUPPORT Other

"HP:0002376 | Developmental regression | Frequent (79-30%)"

Orphanet records developmental regression as a frequent phenotype.

Peripheral Neuropathy OCCASIONAL Peripheral neuropathy (HP:0009830)

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"significant incidence of sensorimotor peripheral polyneuropathy (22.72%)"

Systematic review documents peripheral polyneuropathy in reported FDXR patients.

Movement Disorder FREQUENT Abnormality of movement (HP:0100022)

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"Optic atrophy, movement disorder, and developmental delay were frequent findings. "

Movement disorder identified as frequent in natural history study.

Leigh Syndrome Features on MRI OCCASIONAL Abnormal basal ganglia morphology (HP:0002134)

Growth 1

Failure to Thrive VERY_FREQUENT Failure to thrive (HP:0001508)

Show evidence (1 reference)

ORPHA:543470 SUPPORT Other

"HP:0001508 | Failure to thrive | Very frequent (99-80%)"

Orphanet records failure to thrive as a very frequent phenotype.

🧬

Genetic Associations

1

Autosomal Recessive FDXR Deficiency

Autosomal recessive

💊

Treatments

9

Supportive Care

Action: supportive care MAXO:0000950

Primary management including seizure control with anticonvulsants, visual aids and low vision services, hearing aids or cochlear implants, adequate nutrition, aggressive management of intercurrent infections (known triggers for deterioration), and monitoring for developmental milestones. No disease-modifying therapy is currently available.

Anticonvulsant Therapy

Action: pharmacotherapy MAXO:0000058

Seizure management with anticonvulsants. Standard antiepileptic drugs are used; no MMDS9B-specific pharmacogenomic interactions have been identified.

Cochlear Implantation

Action: surgical procedure MAXO:0000004

Cochlear implantation may be considered for severe auditory neuropathy and hearing loss. Approximately 50% of patients have sensorineural hearing loss amenable to amplification or implantation.

Mitochondrial Cocktail (Empiric)

Action: dietary intervention MAXO:0000088

Empiric mitochondrial supplements including CoQ10, riboflavin, and carnitine are sometimes used in combination with standard supportive care. No evidence of efficacy specific to MMDS9B exists. Used based on general mitochondrial disease management principles.

AAV Gene Therapy (Preclinical)

Action: gene therapy MAXO:0001001

AAV-PHP.B vector carrying Fdxr cDNA demonstrated remarkable efficacy in mouse model. Neonatal administration (P1-P2, 2x10^11 gc/g via facial vein) prevented optic atrophy, restored retinal ganglion cell density (54% loss prevented), restored sciatic nerve myelination and conduction, improved motor function (19/20 treated mice escaped Morris Water Maze vs 1/20 untreated), restored mitochondrial complex I/IV activity, reduced neuroinflammation, and maintained expression at 5 months. FDXR cDNA is 1.485 kb, suitable for AAV packaging. No human trials registered as of 2024. No visible adverse effects in treated mice at 5 months.

Mechanism Target:

RESTORES Mitochondrial Respiratory Chain Dysfunction — AAV-Fdxr restored mitochondrial complex function downstream of Fdxr deficiency in the mouse model.

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"AAV-Fdxr treatment reversed almost all the symptoms of the mutants (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity of the sciatic nerves, prevented optic atrophy, improved mobility, and restored mitochondrial complex function. "

The study explicitly reports restoration of mitochondrial complex function after AAV-Fdxr treatment.

RESTORES Optic Atrophy and Visual Loss — AAV-Fdxr prevented optic atrophy in the treated Fdxr mutant mouse model.

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"AAV-Fdxr treatment reversed almost all the symptoms of the mutants (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity of the sciatic nerves, prevented optic atrophy, improved mobility, and restored mitochondrial complex function. "

The preclinical study reports prevention of optic atrophy after AAV-Fdxr treatment.

RESTORES Peripheral Neuropathy and Demyelination — AAV-Fdxr restored sciatic nerve conduction velocity and improved demyelination-associated pathology in the treated Fdxr mutant mouse model.

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"the impaired conduction velocity (CV) of the sciatic nerves of FdxrR389Q/R389Q mutants was restored after AAV treatment "

Restored sciatic nerve conduction velocity supports a restoring effect on the peripheral neuropathy mechanism in the mouse model.

Target Phenotypes: Optic atrophy ↗ Peripheral neuropathy ↗

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"AAV-Fdxr treatment reversed almost all the symptoms of the mutants (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity of the sciatic nerves, prevented optic atrophy, improved mobility, and restored mitochondrial complex function. "

First demonstration of AAV gene therapy efficacy in Fdxr mutant mice.

Omaveloxolone (Preclinical)

Action: pharmacotherapy MAXO:0000058

Agent: omaveloxolone ↗

NRF2 activator (FDA-approved for Friedreich's ataxia) shown to mitigate ferroptotic pathogenesis in FDXR mouse model and cells. Administration reduced lipid peroxidation and ferroptosis susceptibility caused by NRF2/SLC7A11 pathway disruption. Proposed as an immediate, viable treatment option for FDXR-related disease and other conditions involving aberrant iron metabolism. No human trials for MMDS9B as of 2025.

Mechanism Target:

INHIBITS Ferroptosis via NRF2 Pathway Disruption — Omaveloxolone activates NRF2 and mitigates the ferroptotic FDXR disease mechanism in the preclinical model.

Show evidence (1 reference)

DOI:10.1038/s41420-025-02840-y SUPPORT Model Organism

"administration of the NRF2 activator omaveloxolone , which was recently approved by the FDA for treatment of Friedreich’s ataxia, helps mitigate the pathogenesis. "

The preclinical study supports omaveloxolone as an NRF2-activating inhibitor/modulator of the ferroptotic pathogenesis.

Show evidence (1 reference)

DOI:10.1038/s41420-025-02840-y SUPPORT Model Organism

"administration of the NRF2 activator omaveloxolone , which was recently approved by the FDA for treatment of Friedreich’s ataxia, helps mitigate the pathogenesis. "

Preclinical evidence for omaveloxolone as an NRF2-activating therapeutic strategy in FDXR-related disease.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Essential for all affected families. Autosomal recessive inheritance with 25% recurrence risk per pregnancy for carrier parents. Carrier testing available for at-risk relatives. Carrier screening for p.Arg386Trp proposed for Mexican/Hispanic populations, meeting all standard criteria (significant QoL impact, high carrier frequency, valid test, established genotype-phenotype correlation). Reproductive options include PGT, prenatal diagnosis (CVS/amniocentesis), and donor gametes. Cascade genetic testing recommended for siblings and extended family.

Show evidence (1 reference)

PMID:39669623 SUPPORT Human Clinical

"consideration of a new approach for population carrier screening and development of therapeutics for affected individuals is needed. "

Recommends carrier screening in Mexican population based on high carrier frequency.

Physical Therapy and Rehabilitation

Action: physical therapy MAXO:0000011

Physical therapy for motor deficits from ataxia, neuropathy, and hypotonia. Occupational therapy for adaptive skills in setting of visual and motor impairment. Speech therapy if developmental delay affects communication. Orientation and mobility training for visual impairment.

Vaccination (Preventive)

Action: vaccination MAXO:0001017

Standard childhood immunization schedule should be followed. Since intercurrent infections may trigger neurological deterioration, maintaining up-to-date vaccinations is especially important to prevent vaccine-preventable infections.

🌍

Environmental Factors

2

Acute-Onset Neuropathy Mimicking Inflammatory Disease

Some patients present with acute or subacute onset of peripheral neuropathy that initially mimics inflammatory neuropathy. The underlying mitochondrial etiology becomes apparent only in later stages of disease.

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"Both patients presented with an acute-sub-acute onset of peripheral neuropathy and only in later stages of the disease developed the typical features of FDXR-associated disease "

Documents acute-onset neuropathy in FDXR patients that mimics inflammatory neuropathy at presentation.

Metabolic Stress Susceptibility

Intercurrent infections, prolonged fasting, and extreme physical stress may exacerbate mitochondrial dysfunction. Compromised mitochondria cannot meet increased metabolic demands during illness. Prompt treatment of infections and avoidance of metabolic stressors is recommended.

🔬

Biochemical Markers

6

Mitochondrial Complex I Deficiency

Pathograph Readouts

Readout Of Mitochondrial Respiratory Chain Dysfunction Positive Diagnostic

Complex I deficiency reports impaired respiratory-chain complex assembly/function downstream of FDXR-related iron-sulfur cluster defects.

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"The deficiencies of complex I in the brain, heart, and muscle tissues of the FdxrR389Q/R389Q mutants were all significantly recovered after the AAV treatment "

Complex I deficiency documented in Fdxr mutant mice.

Increased Reactive Oxygen Species

Pathograph Readouts

Readout Of Mitochondrial Respiratory Chain Dysfunction Positive Diagnostic

Increased ROS reports electron-transport dysfunction and oxidative stress in FDXR-deficient cells.

Show evidence (1 reference)

PMID:29040572 SUPPORT In Vitro

"In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). "

In vitro fibroblast assays documented increased ROS in patient cells.

Mitochondrial Iron Overload

Pathograph Readouts

Readout Of Mitochondrial Iron Overload Positive Diagnostic

Increased mitochondrial iron concentration directly reports loss of mitochondrial iron homeostasis downstream of impaired FDXR function.

Show evidence (1 reference)

PMID:32995353 SUPPORT Model Organism

"the FdxrR389Q/R389Q mutants re-acquired iron homeostasis in heart and muscle after AAV treatment "

Ferric iron overload demonstrated in mutant mouse tissues.

Reduced FDXR Enzyme Activity

Pathograph Readouts

Readout Of FDXR Deficiency and Iron-Sulfur Cluster Assembly Impairment Positive Diagnostic

Reduced ferredoxin NADP reductase activity directly reports the proximal FDXR functional deficit.

Show evidence (1 reference)

PMID:29040572 SUPPORT In Vitro

"In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). "

In vitro fibroblast assays documented reduced FDXR enzyme activity.

Decreased Oxygen Consumption Rate

Pathograph Readouts

Readout Of Mitochondrial Respiratory Chain Dysfunction Negative Diagnostic

Decreased OCR reports impaired mitochondrial respiration in patient fibroblasts.

Show evidence (1 reference)

PMID:29040572 SUPPORT In Vitro

"In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). "

Reduced OCR documented in patient fibroblast assays.

Decreased ATP Production

Pathograph Readouts

Readout Of Mitochondrial Respiratory Chain Dysfunction Negative Diagnostic

Decreased ATP production reports impaired oxidative phosphorylation downstream of respiratory-chain dysfunction.

Show evidence (1 reference)

PMID:29040572 SUPPORT In Vitro

"In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). "

Reduced ATP production documented in patient fibroblast assays.

🔀

Differential Diagnoses

7

Conditions with similar clinical presentations that must be differentiated from Multiple Mitochondrial Dysfunctions Syndrome 9B:

Leber Hereditary Optic Neuropathy

Overlapping Features LHON shares optic atrophy but is caused by mitochondrial DNA mutations and typically has acute/subacute onset in young adults. mtDNA testing rules out LHON.

Friedreich Ataxia

Overlapping Features Shares ataxia, neuropathy, and iron dysregulation but is caused by GAA repeat expansion in FXN and has characteristic cardiac involvement. Repeat expansion testing distinguishes the two.

Chronic Inflammatory Demyelinating Polyneuropathy

Overlapping Features FDXR disease can mimic CIDP at onset. Genetic testing distinguishes the two conditions.

Show evidence (1 reference)

PMID:37046037 SUPPORT Human Clinical

"a peripheral neuropathy which can mimic an acute inflammatory disease "

FDXR disease can closely mimic inflammatory neuropathy.

Other MMDS Subtypes

Overlapping Features MMDS types 1-10 caused by variants in ISCA1, ISCA2, NFU1, BOLA3, IBA57, FDX2, and other iron-sulfur cluster assembly genes share overlapping features.

Leigh Syndrome (Other Causes)

Overlapping Features Severe early-onset MMDS9B can present as Leigh syndrome, requiring genetic testing to distinguish from other causes (>75 genes known to cause Leigh syndrome).

Show evidence (1 reference)

PMID:33348459 SUPPORT Human Clinical

"These patients show a broad clinical spectrum ranging from Leigh syndrome with early demise and severe infantile-onset encephalopathy, to milder movement disorders. "

FDXR deficiency can present as Leigh syndrome.

Charcot-Marie-Tooth Disease

Overlapping Features Hereditary peripheral neuropathy that shares sensorimotor neuropathy features with MMDS9B. Distinguished by absence of optic atrophy and auditory neuropathy, and by genetic testing.

Congenital Retinal Dystrophy

Overlapping Features Leber congenital amaurosis and other inherited retinal dystrophies share retinal findings but lack the progressive neurological features of MMDS9B.

{ }

Source YAML

click to show

name: Multiple Mitochondrial Dysfunctions Syndrome 9B
category: Genetic
creation_date: "2026-03-23T00:00:00Z"
updated_date: "2026-05-21T03:15:44Z"
synonyms:
- MMDS9B
- FDXR-related mitochondriopathy
- Ferredoxin reductase deficiency
- FRM
description: >
  Multiple Mitochondrial Dysfunctions Syndrome 9B (MMDS9B; OMIM #620887; Orphanet
  ORPHA:543470) is an autosomal recessive mitochondrial disorder caused by biallelic
  pathogenic variants in the FDXR gene (17q25.1), encoding ferredoxin reductase. FDXR
  is essential for iron-sulfur cluster biogenesis and steroid biosynthesis in the
  mitochondria. Loss of function leads to impaired electron transport, mitochondrial
  iron overload, increased reactive oxygen species, ferroptosis via NRF2 pathway
  disruption, and neurodegeneration with inflammation. FDXR also supports
  mitochondrial cytochrome P450 enzymes for steroidogenesis; severe cases may
  develop adrenal insufficiency. The clinical spectrum ranges from severe infantile encephalopathy
  (Leigh syndrome) with early mortality to milder disease with progressive optic
  atrophy, auditory neuropathy, ataxia, and peripheral neuropathy. Approximately 77
  patients with 59 biallelic mutations have been reported worldwide as of 2024. The p.Arg386Trp hotspot variant is
  common in individuals of Mexican/Hispanic heritage with a carrier frequency of
  ~1:185. MMDS9B is allelic to Auditory Neuropathy and Optic Atrophy (ANOA, OMIM
  #617717). No disease-specific ICD-10 code exists; E88.8 (other specified metabolic
  disorders) is used.
disease_term:
  preferred_term: Multiple mitochondrial dysfunctions syndrome 9B
  term:
    id: MONDO:0971174
    label: multiple mitochondrial dysfunctions syndrome 9B
parents:
- MONDO:0044970
classifications:
  mechanistic_category:
  - classification_value: mitochondrial disease
  harrisons_chapter:
  - classification_value: hereditary disease
prevalence:
  - notes: >
      Ultra-rare. Approximately 62 cases reported worldwide as of 2024. The p.Arg386Trp
      hotspot variant has a carrier frequency of ~1:185 in the Mexican population.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Utilizing recent large-scale genome sequencing surveys, the carrier frequency
          of the p.Arg386Trp variant was estimated as 1 of 185 in the Mexican population.
        explanation: >
          The Campbell 2024 review provides carrier frequency data for the most common
          FDXR variant in the Mexican population.
progression:
  - notes: >
      Variable. Severe early-onset cases present in infancy with Leigh syndrome features
      and may be fatal. Late-onset cases show progressive optic atrophy, auditory neuropathy,
      and ataxia with survival into the second decade and beyond. 18% mortality in published
      cohorts (10/57 with outcome data). Overall survival ~82%. Deaths concentrated in
      severe early-onset phenotype (infants). Key prognostic factors include genotype
      (variants with residual function predict milder disease), age of onset (earlier onset
      predicts worse prognosis), and specific variants (p.Arg386Trp homozygotes tend toward
      severe early-onset). No validated prognostic biomarkers exist, though residual FDXR
      enzyme activity in fibroblasts may correlate with disease severity.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Mortality is high, with 18% of patients, often infants, passing from complications.
        explanation: Documents mortality rate in the largest published cohort.
has_subtypes:
  - name: Severe early-onset
    description: >
      Presents in infancy with encephalopathy, Leigh syndrome features on MRI, seizures,
      severe hypotonia, and rapid neurological deterioration. Often fatal in infancy to
      early childhood (deaths at 10.5 months to ~6 years reported). Associated with more
      damaging FDXR variants. Deaths from progressive neurological decline, respiratory
      failure, or complications of Leigh syndrome.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Mortality is high, with 18% of patients, often infants, passing from complications.
        explanation: Documents the severe early-onset infantile lethality subset of the FDXR-related mitochondriopathy spectrum.
  - name: Classic childhood-onset
    description: >
      Presents in early childhood with progressive optic atrophy, auditory neuropathy,
      developmental delay, ataxia, and peripheral neuropathy. Most common presentation.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Optic atrophy, movement disorder, and developmental delay were frequent findings.
        explanation: >
          The Campbell 2024 natural history study documents the most common presentation of
          FDXR-related mitochondriopathy characterized by optic atrophy and developmental delay.
  - name: Mild late-onset
    description: >
      Later onset with progressive optic atrophy and auditory neuropathy as predominant
      features. Slower progression, survival into second decade and beyond (patients up
      to age 20 documented). Associated with variants retaining residual FDXR function.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          As is common for mitochondrion-related diseases, patients presented with variable
          clinical phenotypes, consistent with mitochondriopathy.
        explanation: >
          Peng et al. document the clinical variability of FDXR mitochondriopathy across 13
          unrelated families, including older surviving individuals (Table 1, patient aged 20 yrs).
pathophysiology:
  - name: FDXR Deficiency and Iron-Sulfur Cluster Assembly Impairment
    description: >
      Biallelic FDXR mutations cause reduced ferredoxin reductase activity, impairing
      electron transfer from NADPH to ferredoxins FDX1 and FDX2. This disrupts
      iron-sulfur cluster assembly, a critical pathway for mitochondrial function.
      FDXR protein has an N-terminal mitochondrial targeting peptide and contains
      FAD (flavin adenine dinucleotide) and NADPH binding domains. Missense variants
      disrupt electron transfer capacity or protein stability. Complete FDXR loss
      is likely lethal across species.
    genes:
      - preferred_term: FDXR
        term:
          id: hgnc:3642
          label: FDXR
    cell_types:
      - preferred_term: Neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: Iron-Sulfur Cluster Assembly
        term:
          id: GO:0016226
          label: iron-sulfur cluster assembly
        modifier: DECREASED
      - preferred_term: Intracellular Iron Ion Homeostasis
        term:
          id: GO:0006879
          label: intracellular iron ion homeostasis
        modifier: DYSREGULATED
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          In vitro enzymatic assays in patient fibroblast cells showed deficient
          ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by
          low oxygen consumption rates (OCRs), complex activities, ATP production and
          increased reactive oxygen species (ROS).
        explanation: >
          Fibroblast assays demonstrating impaired electron transfer and mitochondrial dysfunction
          from FDXR mutations.
    downstream:
      - target: Mitochondrial Respiratory Chain Dysfunction
        causal_link_type: DIRECT
      - target: Impaired Mitochondrial Steroidogenesis
        causal_link_type: DIRECT
      - target: Failure to Thrive
        causal_link_type: UNKNOWN
        description: >
          Systemic mitochondrial dysfunction from FDXR deficiency is associated
          with failure to thrive in the FDXR-related disorder spectrum.
        evidence:
          - reference: ORPHA:543470
            reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
            supports: SUPPORT
            evidence_source: OTHER
            snippet: "HP:0001508 | Failure to thrive | Very frequent (99-80%)"
            explanation: Orphanet records failure to thrive as a very frequent phenotype.
  - name: Impaired Mitochondrial Steroidogenesis
    description: >
      FDXR also transfers electrons to mitochondrial cytochrome P450 enzymes
      required for steroid hormone biosynthesis. FDXR dysfunction can therefore
      impair steroidogenesis and contribute to adrenal insufficiency in severe
      early-onset disease.
    biological_processes:
      - preferred_term: Steroid Biosynthetic Process
        term:
          id: GO:0006694
          label: steroid biosynthetic process
        modifier: DECREASED
    downstream:
      - target: Adrenal Insufficiency
        causal_link_type: DIRECT
  - name: Mitochondrial Respiratory Chain Dysfunction
    description: >
      FDXR deficiency leads to reduced activity of mitochondrial complexes I, II, III,
      and IV due to impaired iron-sulfur cluster incorporation into respiratory chain
      components. This causes decreased ATP production and increased ROS.
    biological_processes:
      - preferred_term: Electron Transport Chain
        term:
          id: GO:0022900
          label: electron transport chain
        modifier: DECREASED
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          The deficiencies of complex I in the brain, heart, and muscle tissues of the
          FdxrR389Q/R389Q mutants were all significantly recovered after the AAV treatment
        explanation: >
          Demonstrates that Fdxr mutation causes mitochondrial complex deficiencies
          that can be reversed with gene therapy.
    downstream:
      - target: Mitochondrial Iron Overload
        causal_link_type: DIRECT
      - target: Neurodegeneration
        causal_link_type: DIRECT
      - target: Neuroinflammation
        causal_link_type: DIRECT
  - name: Mitochondrial Iron Overload
    description: >
      Loss of FDXR function causes iron accumulation in mitochondria due to impaired
      iron-sulfur cluster synthesis. Mitochondrial iron overload accelerates ROS
      production and enhances oxidative stress, contributing to cellular damage.
    biological_processes:
      - preferred_term: Intracellular Iron Ion Homeostasis
        term:
          id: GO:0006879
          label: intracellular iron ion homeostasis
        modifier: DYSREGULATED
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          the FdxrR389Q/R389Q mutants re-acquired iron homeostasis in heart and muscle
          after AAV treatment
        explanation: >
          Demonstrates mitochondrial iron overload in Fdxr mutant mice that is reversed
          by gene therapy.
    downstream:
      - target: Ferroptosis via NRF2 Pathway Disruption
        causal_link_type: DIRECT
      - target: Neurodegeneration
        causal_link_type: DIRECT
      - target: Neuroinflammation
        causal_link_type: DIRECT
  - name: Ferroptosis via NRF2 Pathway Disruption
    description: >
      Mitochondrial iron overload from FDXR deficiency increases lipid peroxidation in
      inner mitochondrial and plasma membranes, leading to ferroptotic cell death.
      Disruption of the NRF2 pathway and its target gene SLC7A11 plays a key role in
      this pathogenic process. NRF2 activation with omaveloxolone mitigates pathogenesis
      in preclinical models, suggesting ferroptosis as a tractable therapeutic target.
    biological_processes:
      - preferred_term: Lipid Oxidation
        term:
          id: GO:0034440
          label: lipid oxidation
        modifier: INCREASED
      - preferred_term: Response to Oxidative Stress
        term:
          id: GO:0006979
          label: response to oxidative stress
        modifier: INCREASED
    evidence:
      - reference: DOI:10.1038/s41420-025-02840-y
        reference_title: "Ferroptosis is a novel pathogenic mechanism of FDXR-related disease via disruption of the NRF2 pathway"
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          We demonstrated increased lipid peroxidation in the inner mitochondrial and
          plasma membranes, resulting in susceptibility to ferroptosis. Closer examination
          revealed that disruption of the NRF2 pathway and its target gene SLC7A11 appear
          to play important roles in this pathogenic process.
        explanation: >
          Mouse model and cell studies demonstrate ferroptosis as a novel pathogenic
          mechanism in FDXR-related disease via NRF2/SLC7A11 disruption.
    downstream:
      - target: Neurodegeneration
        causal_link_type: DIRECT
  - name: Neurodegeneration
    description: >
      FDXR mutations cause progressive neurodegeneration with Fluoro-Jade C positivity
      in cerebellum, cerebral cortex, and hippocampus. Neuronal loss is the primary
      driver of clinical features including optic atrophy, ataxia, and neuropathy.
      FDXR deficiency may also destabilize p53/TP73, contributing to impaired
      apoptotic regulation and potential spontaneous tumor susceptibility as
      demonstrated in the mouse model.
    cell_types:
      - preferred_term: Neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: Apoptotic Process
        term:
          id: GO:0006915
          label: apoptotic process
        modifier: INCREASED
    evidence:
      - reference: PMID:30250212
        reference_title: "Biallelic mutations in FDXR cause neurodegeneration associated with inflammation."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          we expand upon those results by describing two new cases of disease-causing FDXR
          variants in patients with variable severity of phenotypes, including evidence of
          an inflammatory response in brain autopsy
        explanation: >
          Describes neurodegeneration in FDXR patients with brain autopsy findings
          and mouse model showing Fluoro-Jade C positivity.
    downstream:
      - target: Optic Atrophy and Visual Loss
        causal_link_type: DIRECT
      - target: Peripheral Neuropathy and Demyelination
        causal_link_type: DIRECT
      - target: Auditory Neuropathy
        causal_link_type: UNKNOWN
        description: >
          Auditory neuropathy is a common clinical manifestation within the
          FDXR neurodegenerative mitochondriopathy spectrum.
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              The most common presentation includes optic and/or auditory
              neuropathy, variably associated to developmental delay or regression,
              global hypotonia, pyramidal, cerebellar signs, and seizures.
            explanation: >
              The review places auditory neuropathy among the common neurologic
              manifestations of FDXR-associated disease.
      - target: Ataxia
        causal_link_type: UNKNOWN
        description: >
          Ataxia is a frequent neurologic manifestation of the FDXR
          neurodegenerative disease spectrum.
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "significant incidence of sensorimotor peripheral polyneuropathy (22.72%) and ataxia (43.18%)"
            explanation: >
              The review reports ataxia as a frequent manifestation in FDXR
              patients.
      - target: Developmental Delay
        causal_link_type: UNKNOWN
        description: >
          Developmental delay is a frequent neurodevelopmental manifestation of
          FDXR-related mitochondrial dysfunction.
        evidence:
          - reference: PMID:39669623
            reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Optic atrophy, movement disorder, and developmental delay were frequent
              findings.
            explanation: >
              Natural-history data identify developmental delay as a frequent
              finding in ferredoxin-reductase-related mitochondriopathy.
      - target: Developmental Regression
        causal_link_type: UNKNOWN
        description: >
          Developmental regression is a distinct neurodevelopmental manifestation
          within the FDXR-related disorder spectrum.
        evidence:
          - reference: ORPHA:543470
            reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
            supports: SUPPORT
            evidence_source: OTHER
            snippet: "HP:0002376 | Developmental regression | Frequent (79-30%)"
            explanation: Orphanet records developmental regression as a frequent phenotype.
      - target: Movement Disorder
        causal_link_type: UNKNOWN
        description: >
          Movement disorder is a frequent neurologic manifestation of the same
          FDXR disease spectrum.
        evidence:
          - reference: PMID:39669623
            reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Optic atrophy, movement disorder, and developmental delay were frequent
              findings.
            explanation: >
              Natural-history data identify movement disorder as a frequent
              finding in ferredoxin-reductase-related mitochondriopathy.
      - target: Hypotonia
        causal_link_type: UNKNOWN
        description: >
          Global hypotonia is part of the common neurologic presentation of
          FDXR-related disease.
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              The most common presentation includes optic and/or auditory
              neuropathy, variably associated to developmental delay or regression,
              global hypotonia, pyramidal, cerebellar signs, and seizures.
            explanation: >
              The review lists global hypotonia among common manifestations of
              FDXR-associated disease.
      - target: Seizures
        causal_link_type: UNKNOWN
        description: >
          Seizures can accompany the neurologic FDXR disease presentation.
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              The most common presentation includes optic and/or auditory
              neuropathy, variably associated to developmental delay or regression,
              global hypotonia, pyramidal, cerebellar signs, and seizures.
            explanation: >
              The review lists seizures among common manifestations of
              FDXR-associated disease.
      - target: Leigh Syndrome Features on MRI
        causal_link_type: UNKNOWN
        description: >
          Severe FDXR-related mitochondrial disease can present with Leigh
          syndrome and severe infantile encephalopathy.
        evidence:
          - reference: PMID:33348459
            reference_title: "Expanding the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of uncertain significance."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              broad clinical spectrum ranging from Leigh syndrome with early demise and
              severe infantile-onset encephalopathy, to milder movement disorders.
            explanation: >
              This cohort expansion supports Leigh syndrome as a severe-end
              manifestation of FDXR deficiency.
      - target: Spasticity
        causal_link_type: UNKNOWN
        description: >
          Spasticity occurs within the FDXR neurodegenerative mitochondriopathy
          spectrum.
        evidence:
          - reference: PMID:29040572
            reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Other less common features included spasticity and respiratory failure.
            explanation: >
              The original FDXR cohort reports spasticity among additional
              neurologic manifestations.
      - target: Microcephaly
        causal_link_type: UNKNOWN
        description: >
          Microcephaly is part of the reported FDXR-related neurodevelopmental
          phenotype spectrum.
        evidence:
          - reference: ORPHA:543470
            reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
            supports: SUPPORT
            evidence_source: OTHER
            snippet: "Additional common manifestations include global developmental delay with or without regression, neuropathy, spasticity, and microcephaly"
            explanation: >
              Orphanet lists microcephaly among additional manifestations of the
              FDXR-related disorder.
      - target: Feeding Difficulty
        causal_link_type: UNKNOWN
        description: >
          Severe infantile FDXR-related disease can include impaired feeding in
          the setting of broader neurologic and systemic involvement.
        evidence:
          - reference: PMID:30250212
            reference_title: "Biallelic mutations in FDXR cause neurodegeneration associated with inflammation."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              She then spent 2.5 months in neonatal intensive care unit for poor feeding,
              abdominal distension, and initial respiratory distress syndrome.
            explanation: >
              The case description supports feeding difficulty as a severe
              clinical manifestation in an FDXR patient.
  - name: Neuroinflammation
    description: >
      FDXR-related neurodegeneration is accompanied by reactive gliosis with increased
      GFAP-positive astrocytes. Brain autopsy and mouse model show astrogliosis in
      cerebellum, cerebral cortex, and hippocampus, indicating a secondary inflammatory
      response to neuronal injury.
    cell_types:
      - preferred_term: Astrocyte
        term:
          id: CL:0000127
          label: astrocyte
    biological_processes:
      - preferred_term: Inflammatory Response
        term:
          id: GO:0006954
          label: inflammatory response
        modifier: INCREASED
    evidence:
      - reference: PMID:30250212
        reference_title: "Biallelic mutations in FDXR cause neurodegeneration associated with inflammation."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          we expand upon those results by describing two new cases of disease-causing FDXR
          variants in patients with variable severity of phenotypes, including evidence of
          an inflammatory response in brain autopsy
        explanation: >
          Documents neuroinflammation with astrogliosis in FDXR patient brain autopsy
          and increased GFAP in mouse model.
  - name: Optic Atrophy and Visual Loss
    description: >
      Progressive optic nerve atrophy with loss of retinal ganglion cells. Present in
      approximately 93% of patients. Leads to progressive visual loss, often to legal
      blindness. Retinal dystrophy with attenuated vessels and retinal vascular occlusion
      may also occur as distinct clinical characteristics.
    cell_types:
      - preferred_term: Retinal ganglion cell
        term:
          id: CL:0000740
          label: retinal ganglion cell
    biological_processes:
      - preferred_term: Apoptotic Process
        term:
          id: GO:0006915
          label: apoptotic process
        modifier: INCREASED
    evidence:
      - reference: PMID:37481223
        reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          all patients presented with retinal dystrophy, and electroretinogram showed
          severely impaired cone and rod functions in their first decades
        explanation: >
          Documents retinal dystrophy and vascular abnormalities in FDXR patients.
    downstream:
      - target: Optic Atrophy
        causal_link_type: DIRECT
        description: >
          Retinal ganglion cell and optic nerve involvement manifests clinically as
          optic atrophy and progressive visual loss.
        evidence:
          - reference: PMID:39669623
            reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Optic atrophy, movement disorder, and developmental delay were frequent
              findings.
            explanation: >
              Natural-history data identify optic atrophy as a frequent finding
              in ferredoxin-reductase-related mitochondriopathy.
      - target: Retinal Dystrophy
        causal_link_type: UNKNOWN
        description: >
          Retinal dystrophy is an ocular manifestation reported alongside optic
          atrophy in FDXR-associated disease.
        evidence:
          - reference: PMID:37481223
            reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              In addition to optic atrophy and diverse extraocular manifestations,
              all patients presented with retinal dystrophy, and electroretinogram
              showed severely impaired cone and rod functions in their first decades.
            explanation: >
              The ocular cohort directly supports retinal dystrophy as part of
              the FDXR-associated ocular phenotype.
      - target: Nystagmus
        causal_link_type: UNKNOWN
        description: >
          Nystagmus is an ocular manifestation reported with FDXR-related optic
          atrophy and retinal disease.
        evidence:
          - reference: PMID:39746537
            reference_title: "Ocular and neurological manifestations of the FDXR-related disorder."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Our review of the existing literature reveals other common ocular findings
              of myopia, nystagmus, strabismus, retinal dystrophy, attenuation of
              retinal vessels, and cataracts.
            explanation: >
              This ophthalmology review places nystagmus among common ocular
              manifestations of FDXR-related disorder.
      - target: Strabismus
        causal_link_type: UNKNOWN
        description: >
          Strabismus is another ocular manifestation reported in the FDXR-related
          ocular phenotype spectrum.
        evidence:
          - reference: PMID:39746537
            reference_title: "Ocular and neurological manifestations of the FDXR-related disorder."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Our review of the existing literature reveals other common ocular findings
              of myopia, nystagmus, strabismus, retinal dystrophy, attenuation of
              retinal vessels, and cataracts.
            explanation: >
              This ophthalmology review places strabismus among common ocular
              manifestations of FDXR-related disorder.
  - name: Peripheral Neuropathy and Demyelination
    description: >
      Sensorimotor peripheral neuropathy with demyelination of sciatic and other peripheral
      nerves. Present in ~23% of patients. Contributes to ataxia, hypotonia, and motor
      disability.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          The review of clinical findings in previously described cases from literature
          reveals also a significant incidence of sensorimotor peripheral polyneuropathy
          (22.72%) and ataxia (43.18%)
        explanation: >
          Systematic review documenting frequency of peripheral neuropathy and ataxia
          in FDXR patients.
    downstream:
      - target: Peripheral Neuropathy
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "significant incidence of sensorimotor peripheral polyneuropathy (22.72%)"
            explanation: >
              The review documents sensorimotor peripheral polyneuropathy as a clinical
              manifestation of FDXR-associated disease.
  - name: Acute-Onset Peripheral Neuropathy
    description: >
      Some patients present with acute or subacute onset of peripheral neuropathy that
      can mimic inflammatory neuropathy. Only in later stages do typical features of
      FDXR-associated disease become apparent. Intercurrent infections may trigger acute
      neurological deterioration, as compromised mitochondria cannot meet increased
      metabolic demands during febrile stress.
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Both patients presented with an acute-sub-acute onset of peripheral neuropathy
          and only in later stages of the disease developed the typical features of
          FDXR-associated disease
        explanation: >
          Describes acute-onset neuropathy presentation that can mimic inflammatory peripheral neuropathy.
    downstream:
      - target: Peripheral Neuropathy
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:37046037
            reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "RESULTS: Both patients presented with an acute-sub-acute onset of peripheral \nneuropathy and only in later stages of the disease developed the typical \nfeatures of FDXR-associated disease."
            explanation: >
              The acute-onset presentation is explicitly a peripheral neuropathy
              presentation of FDXR-associated disease.
phenotypes:
  - category: Neurological
    name: Optic Atrophy
    frequency: VERY_FREQUENT
    description: >
      Progressive optic nerve atrophy present in ~93% of patients. Leads to progressive
      visual loss, often to legal blindness. May present with pale optic discs on
      fundoscopy.
    phenotype_term:
      preferred_term: Optic atrophy
      term:
        id: HP:0000648
        label: Optic atrophy
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Optic atrophy, movement disorder, and developmental delay were frequent findings.
        explanation: Optic atrophy identified as one of the most frequent findings in the natural history study.
  - category: Neurological
    name: Auditory Neuropathy
    frequency: FREQUENT
    description: >
      Progressive sensorineural hearing loss present in ~50% of patients. May be
      amenable to cochlear implantation.
    phenotype_term:
      preferred_term: Sensorineural hearing impairment
      term:
        id: HP:0000407
        label: Sensorineural hearing impairment
  - category: Neurological
    name: Ataxia
    frequency: FREQUENT
    description: >
      Present in 43.18% of patients. Contributes to gait instability and motor
      disability. Both cerebellar and sensory components may be present.
    phenotype_term:
      preferred_term: Ataxia
      term:
        id: HP:0001251
        label: Ataxia
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          The review of clinical findings in previously described cases from literature
          reveals also a significant incidence of sensorimotor peripheral polyneuropathy
          (22.72%) and ataxia (43.18%)
        explanation: Systematic review documenting 43% frequency of ataxia.
  - category: Neurological
    name: Hypotonia
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Hypotonia
      term:
        id: HP:0001252
        label: Hypotonia
  - category: Neurological
    name: Seizures
    frequency: OCCASIONAL
    description: >
      Present in a significant proportion of patients. Managed with anticonvulsants
      as part of supportive care.
    phenotype_term:
      preferred_term: Seizure
      term:
        id: HP:0001250
        label: Seizure
  - category: Neurological
    name: Developmental Delay
    frequency: FREQUENT
    description: >
      Global developmental delay present in ~53% of patients. May progress to
      intellectual disability in severe cases.
    phenotype_term:
      preferred_term: Global developmental delay
      term:
        id: HP:0001263
        label: Global developmental delay
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Optic atrophy, movement disorder, and developmental delay were frequent findings.
        explanation: Developmental delay identified as a frequent finding in natural history study.
  - category: Neurological
    name: Developmental Regression
    frequency: FREQUENT
    description: >
      Developmental regression is a frequent neurodevelopmental manifestation
      reported in the FDXR-related disorder spectrum.
    phenotype_term:
      preferred_term: Developmental regression
      term:
        id: HP:0002376
        label: Developmental regression
    evidence:
      - reference: ORPHA:543470
        reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "HP:0002376 | Developmental regression | Frequent (79-30%)"
        explanation: Orphanet records developmental regression as a frequent phenotype.
  - category: Neurological
    name: Peripheral Neuropathy
    frequency: OCCASIONAL
    description: >
      Sensorimotor peripheral polyneuropathy present in ~23% of patients. Can mimic
      inflammatory neuropathy at onset.
    phenotype_term:
      preferred_term: Peripheral neuropathy
      term:
        id: HP:0009830
        label: Peripheral neuropathy
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "significant incidence of sensorimotor peripheral polyneuropathy (22.72%)"
        explanation: >
          Systematic review documents peripheral polyneuropathy in reported FDXR
          patients.
  - category: Neurological
    name: Nystagmus
    frequency: OCCASIONAL
    description: >
      Nystagmus is reported among ocular manifestations of the FDXR-related
      disorder.
    phenotype_term:
      preferred_term: Nystagmus
      term:
        id: HP:0000639
        label: Nystagmus
    evidence:
      - reference: ORPHA:543470
        reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "HP:0000639 | Nystagmus | Occasional (29-5%)"
        explanation: Orphanet records nystagmus as an occasional phenotype.
  - category: Ophthalmologic
    name: Retinal Dystrophy
    frequency: FREQUENT
    description: >
      Retinal dystrophy with attenuated retinal vessels appearing as white lines.
      Retinal vascular occlusion may be a distinct clinical characteristic.
    phenotype_term:
      preferred_term: Retinal dystrophy
      term:
        id: HP:0000556
        label: Retinal dystrophy
    evidence:
      - reference: PMID:37481223
        reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Retinal dystrophy with attenuated retinal vessels appearing as white lines was
          observed in this cohort, and the FFA images revealed that retinal vascular
          occlusion could be a distinct clinical characteristic
        explanation: Documents retinal dystrophy with characteristic vascular findings.
  - category: Neurological
    name: Movement Disorder
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Abnormality of movement
      term:
        id: HP:0100022
        label: Abnormality of movement
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Optic atrophy, movement disorder, and developmental delay were frequent findings.
        explanation: Movement disorder identified as frequent in natural history study.
  - category: Neuroimaging
    name: Leigh Syndrome Features on MRI
    frequency: OCCASIONAL
    description: >
      Bilateral symmetric basal ganglia signal abnormalities (Leigh syndrome pattern),
      cerebellar atrophy, cerebral atrophy, and optic nerve thinning. Pattern correlates
      with disease severity.
    phenotype_term:
      preferred_term: Abnormal basal ganglia morphology
      term:
        id: HP:0002134
        label: Abnormal basal ganglia morphology
  - category: Ophthalmologic
    name: Strabismus
    description: >
      Strabismus is reported among ocular findings in the FDXR-related disorder.
    phenotype_term:
      preferred_term: Strabismus
      term:
        id: HP:0000486
        label: Strabismus
    evidence:
      - reference: PMID:39746537
        reference_title: "Ocular and neurological manifestations of the FDXR-related disorder."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Our review of the existing literature reveals other common ocular findings
          of myopia, nystagmus, strabismus, retinal dystrophy, attenuation of retinal
          vessels, and cataracts.
        explanation: The review reports strabismus among ocular manifestations of FDXR-related disorder.
  - category: Neurological
    name: Spasticity
    frequency: FREQUENT
    description: >
      Spasticity is a recurrent neurologic manifestation in FDXR-related
      mitochondriopathy.
    phenotype_term:
      preferred_term: Spasticity
      term:
        id: HP:0001257
        label: Spasticity
    evidence:
      - reference: ORPHA:543470
        reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "HP:0001257 | Spasticity | Frequent (79-30%)"
        explanation: Orphanet records spasticity as a frequent phenotype.
  - category: Neurological
    name: Microcephaly
    frequency: OCCASIONAL
    description: >
      Microcephaly is reported in a subset of patients with FDXR-related
      neurodevelopmental disease.
    phenotype_term:
      preferred_term: Microcephaly
      term:
        id: HP:0000252
        label: Microcephaly
    evidence:
      - reference: ORPHA:543470
        reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "HP:0000252 | Microcephaly | Occasional (29-5%)"
        explanation: Orphanet records microcephaly as an occasional phenotype.
  - category: Neurological
    name: Feeding Difficulty
    description: >
      Severe infantile FDXR-related disease can include poor feeding, broadening
      the clinical spectrum beyond optic atrophy and neuropathy.
    phenotype_term:
      preferred_term: Feeding difficulties
      term:
        id: HP:0011968
        label: Feeding difficulties
    evidence:
      - reference: PMID:30250212
        reference_title: "Biallelic mutations in FDXR cause neurodegeneration associated with inflammation."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          She then spent 2.5 months in neonatal intensive care unit for poor feeding,
          abdominal distension, and initial respiratory distress syndrome.
        explanation: >
          The case description documents poor feeding in a severely affected
          infant with biallelic FDXR variants.
  - category: Nutritional
    name: Failure to Thrive
    frequency: VERY_FREQUENT
    description: >
      Failure to thrive is very frequently reported in MMDS9B, consistent with
      systemic metabolic disease burden.
    phenotype_term:
      preferred_term: Failure to thrive
      term:
        id: HP:0001508
        label: Failure to thrive
    evidence:
      - reference: ORPHA:543470
        reference_title: "Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome (Orphanet structured-database record)"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "HP:0001508 | Failure to thrive | Very frequent (99-80%)"
        explanation: Orphanet records failure to thrive as a very frequent phenotype.
  - category: Endocrine
    name: Adrenal Insufficiency
    frequency: OCCASIONAL
    description: >
      Adrenal insufficiency and disorders of sexual development documented in severe
      early-onset FDXR-related mitochondriopathy cases, consistent with FDXR's role in
      mitochondrial P450 electron transfer for steroidogenesis. May compound clinical
      deterioration during stress or infection.
    phenotype_term:
      preferred_term: Adrenal insufficiency
      term:
        id: HP:0000846
        label: Adrenal insufficiency
biochemical:
  - name: Mitochondrial Complex I Deficiency
    readouts:
      - target: Mitochondrial Respiratory Chain Dysfunction
        relationship: READOUT_OF
        direction: POSITIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Complex I deficiency reports impaired respiratory-chain complex
          assembly/function downstream of FDXR-related iron-sulfur cluster defects.
    notes: >
      Reduced activity of mitochondrial respiratory chain complex I in patient fibroblasts
      and tissues.
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          The deficiencies of complex I in the brain, heart, and muscle tissues of the
          FdxrR389Q/R389Q mutants were all significantly recovered after the AAV treatment
        explanation: Complex I deficiency documented in Fdxr mutant mice.
  - name: Increased Reactive Oxygen Species
    readouts:
      - target: Mitochondrial Respiratory Chain Dysfunction
        relationship: READOUT_OF
        direction: POSITIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Increased ROS reports electron-transport dysfunction and oxidative
          stress in FDXR-deficient cells.
    notes: >
      Significant increase in ROS production in patient cells due to impaired electron
      transport chain function and mitochondrial iron overload.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          In vitro enzymatic assays in patient fibroblast cells showed deficient
          ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by
          low oxygen consumption rates (OCRs), complex activities, ATP production and
          increased reactive oxygen species (ROS).
        explanation: >
          In vitro fibroblast assays documented increased ROS in patient cells.
  - name: Mitochondrial Iron Overload
    readouts:
      - target: Mitochondrial Iron Overload
        relationship: READOUT_OF
        direction: POSITIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Increased mitochondrial iron concentration directly reports loss of
          mitochondrial iron homeostasis downstream of impaired FDXR function.
    notes: >
      Accumulation of iron in mitochondria due to impaired iron-sulfur cluster synthesis.
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          the FdxrR389Q/R389Q mutants re-acquired iron homeostasis in heart and muscle
          after AAV treatment
        explanation: Ferric iron overload demonstrated in mutant mouse tissues.
  - name: Reduced FDXR Enzyme Activity
    readouts:
      - target: FDXR Deficiency and Iron-Sulfur Cluster Assembly Impairment
        relationship: READOUT_OF
        direction: POSITIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Reduced ferredoxin NADP reductase activity directly reports the
          proximal FDXR functional deficit.
    notes: >
      Decreased ferredoxin NADP reductase activity measured in patient fibroblasts.
      Activity levels correlate with disease severity. FDXR activity 33-49% of wild-type
      in the mouse model.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          In vitro enzymatic assays in patient fibroblast cells showed deficient
          ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by
          low oxygen consumption rates (OCRs), complex activities, ATP production and
          increased reactive oxygen species (ROS).
        explanation: In vitro fibroblast assays documented reduced FDXR enzyme activity.
  - name: Decreased Oxygen Consumption Rate
    readouts:
      - target: Mitochondrial Respiratory Chain Dysfunction
        relationship: READOUT_OF
        direction: NEGATIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Decreased OCR reports impaired mitochondrial respiration in patient
          fibroblasts.
    notes: >
      Low oxygen consumption rates (OCRs) in patient fibroblasts reflecting
      mitochondrial respiratory chain dysfunction.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          In vitro enzymatic assays in patient fibroblast cells showed deficient
          ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by
          low oxygen consumption rates (OCRs), complex activities, ATP production and
          increased reactive oxygen species (ROS).
        explanation: Reduced OCR documented in patient fibroblast assays.
  - name: Decreased ATP Production
    readouts:
      - target: Mitochondrial Respiratory Chain Dysfunction
        relationship: READOUT_OF
        direction: NEGATIVE
        endpoint_context: DIAGNOSTIC
        interpretation: >
          Decreased ATP production reports impaired oxidative phosphorylation
          downstream of respiratory-chain dysfunction.
    notes: >
      Reduced ATP production in patient cells due to impaired mitochondrial
      respiratory chain function.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          In vitro enzymatic assays in patient fibroblast cells showed deficient
          ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by
          low oxygen consumption rates (OCRs), complex activities, ATP production and
          increased reactive oxygen species (ROS).
        explanation: Reduced ATP production documented in patient fibroblast assays.
genetic:
  - name: Autosomal Recessive FDXR Deficiency
    gene_term:
      preferred_term: FDXR
      term:
        id: hgnc:3642
        label: FDXR
    inheritance:
      - name: Autosomal recessive
        penetrance: COMPLETE
        expressivity: VARIABLE
        evidence:
          - reference: PMID:29040572
            reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              we conducted whole-exome sequencing of patients with optic atrophy and other
              neurological signs of mitochondriopathy and identified 17 individuals from
              13 unrelated families with recessive mutations in FDXR
            explanation: Original study identifying recessive FDXR mutations in 17 patients from 13 families.
    variants:
      - name: FDXR p.Arg386Trp hotspot variant
        description: >
          The most common pathogenic variant, found in ~25% of cases. Also reported as
          p.Arg392Trp under alternative transcript numbering (NM_024417.4 vs NM_001258012.2).
          Homozygosity or compound heterozygosity with this variant is particularly common
          in individuals of Mexican/Hispanic heritage. Carrier frequency ~1:185 in Mexican
          population. Located in the FAD binding domain. The corresponding mouse residue
          (Arg389) was used in the Fdxr(R389Q) model, though the mouse carries a Gln
          substitution rather than Trp.
        gene:
          preferred_term: FDXR
          term:
            id: hgnc:3642
            label: FDXR
        evidence:
          - reference: PMID:39669623
            reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Notably, 25% of cases were homozygous or compound heterozygous for the
              previously reported p.Arg386Trp "hotspot" variant. Of the obtained ancestry,
              all but 1 individual heterozygous for the p.Arg386Trp variant was Hispanic,
              with many reporting Mexican heritage.
            explanation: Documents the hotspot variant frequency and ethnic predilection.
          - reference: PMID:29040572
            reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              we found that mice carrying a spontaneous mutation allelic to the most
              common mutation found in patients displayed progressive gait abnormalities
              and vision loss, in addition to biochemical defects consistent with the
              major clinical features of the disease
            explanation: >
              Original cohort identified this as one of the most frequently reported variants,
              with an allelic mouse model at the corresponding residue.
      - name: FDXR missense variants
        description: >
          Over 80% of pathogenic FDXR variants are missense, affecting protein function
          by disrupting electron transfer or protein stability. Variants occur across
          multiple functional domains including the N-terminal mitochondrial targeting
          peptide, FAD binding domain, and NADPH binding domain.
        gene:
          preferred_term: FDXR
          term:
            id: hgnc:3642
            label: FDXR
        evidence:
          - reference: PMID:33348459
            reference_title: "Expanding the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of uncertain significance."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Over 80% of these variants are missense, a challenging variant class in
              which to determine pathogenic consequence
            explanation: Stenton et al. document the predominance of missense variants.
      - name: FDXR novel Chinese cohort variants
        description: >
          Five novel FDXR variants identified in Chinese families including c.383C>T
          (p.A128V), c.963delG (p.R322fs*7), c.1052_1053delTC (p.L351Pfs*12),
          c.394-11T>G and c.1002+1G>A.
        gene:
          preferred_term: FDXR
          term:
            id: hgnc:3642
            label: FDXR
        evidence:
          - reference: PMID:37481223
            reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >
              Five novel FDXR variants were identified: c.383C > T (p.A128V), c.963delG
              (p.R322fs*7), c.1052_1053delTC (p.L351Pfs*12), c.394-11T > G and c.1002+1G > A.
            explanation: Novel variants expanding the genetic spectrum in Chinese patients.
environmental:
  - name: Acute-Onset Neuropathy Mimicking Inflammatory Disease
    description: >
      Some patients present with acute or subacute onset of peripheral neuropathy
      that initially mimics inflammatory neuropathy. The underlying mitochondrial
      etiology becomes apparent only in later stages of disease.
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Both patients presented with an acute-sub-acute onset of peripheral neuropathy
          and only in later stages of the disease developed the typical features of
          FDXR-associated disease
        explanation: >
          Documents acute-onset neuropathy in FDXR patients that mimics inflammatory
          neuropathy at presentation.
  - name: Metabolic Stress Susceptibility
    description: >
      Intercurrent infections, prolonged fasting, and extreme physical stress may
      exacerbate mitochondrial dysfunction. Compromised mitochondria cannot meet increased
      metabolic demands during illness. Prompt treatment of infections and avoidance of
      metabolic stressors is recommended.
treatments:
  - name: Supportive Care
    description: >
      Primary management including seizure control with anticonvulsants, visual aids
      and low vision services, hearing aids or cochlear implants, adequate nutrition,
      aggressive management of intercurrent infections (known triggers for deterioration),
      and monitoring for developmental milestones. No disease-modifying therapy is
      currently available.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
  - name: Anticonvulsant Therapy
    description: >
      Seizure management with anticonvulsants. Standard antiepileptic drugs are used;
      no MMDS9B-specific pharmacogenomic interactions have been identified.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
  - name: Cochlear Implantation
    description: >
      Cochlear implantation may be considered for severe auditory neuropathy and
      hearing loss. Approximately 50% of patients have sensorineural hearing loss
      amenable to amplification or implantation.
    treatment_term:
      preferred_term: surgical procedure
      term:
        id: MAXO:0000004
        label: surgical procedure
  - name: Mitochondrial Cocktail (Empiric)
    description: >
      Empiric mitochondrial supplements including CoQ10, riboflavin, and carnitine
      are sometimes used in combination with standard supportive care. No evidence
      of efficacy specific to MMDS9B exists. Used based on general mitochondrial
      disease management principles.
    treatment_term:
      preferred_term: dietary intervention
      term:
        id: MAXO:0000088
        label: dietary intervention
  - name: AAV Gene Therapy (Preclinical)
    description: >
      AAV-PHP.B vector carrying Fdxr cDNA demonstrated remarkable efficacy in mouse model.
      Neonatal administration (P1-P2, 2x10^11 gc/g via facial vein) prevented optic
      atrophy, restored retinal ganglion cell density (54% loss prevented), restored
      sciatic nerve myelination and conduction, improved motor function (19/20 treated
      mice escaped Morris Water Maze vs 1/20 untreated), restored mitochondrial complex
      I/IV activity, reduced neuroinflammation, and maintained expression at 5 months.
      FDXR cDNA is 1.485 kb, suitable for AAV packaging. No human trials registered as
      of 2024. No visible adverse effects in treated mice at 5 months.
    treatment_term:
      preferred_term: gene therapy
      term:
        id: MAXO:0001001
        label: gene therapy
    target_mechanisms:
      - target: Mitochondrial Respiratory Chain Dysfunction
        treatment_effect: RESTORES
        description: >
          AAV-Fdxr restored mitochondrial complex function downstream of Fdxr
          deficiency in the mouse model.
        evidence:
          - reference: PMID:32995353
            reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
            supports: SUPPORT
            evidence_source: MODEL_ORGANISM
            snippet: >
              AAV-Fdxr treatment reversed almost all the symptoms of the mutants
              (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity
              of the sciatic nerves, prevented optic atrophy, improved mobility, and
              restored mitochondrial complex function.
            explanation: >
              The study explicitly reports restoration of mitochondrial complex
              function after AAV-Fdxr treatment.
      - target: Optic Atrophy and Visual Loss
        treatment_effect: RESTORES
        description: >
          AAV-Fdxr prevented optic atrophy in the treated Fdxr mutant mouse model.
        evidence:
          - reference: PMID:32995353
            reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
            supports: SUPPORT
            evidence_source: MODEL_ORGANISM
            snippet: >
              AAV-Fdxr treatment reversed almost all the symptoms of the mutants
              (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity
              of the sciatic nerves, prevented optic atrophy, improved mobility, and
              restored mitochondrial complex function.
            explanation: >
              The preclinical study reports prevention of optic atrophy after
              AAV-Fdxr treatment.
      - target: Peripheral Neuropathy and Demyelination
        treatment_effect: RESTORES
        description: >
          AAV-Fdxr restored sciatic nerve conduction velocity and improved
          demyelination-associated pathology in the treated Fdxr mutant mouse model.
        evidence:
          - reference: PMID:32995353
            reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
            supports: SUPPORT
            evidence_source: MODEL_ORGANISM
            snippet: >
              the impaired conduction velocity (CV) of the sciatic nerves of
              FdxrR389Q/R389Q mutants was restored after AAV treatment
            explanation: >
              Restored sciatic nerve conduction velocity supports a restoring
              effect on the peripheral neuropathy mechanism in the mouse model.
    target_phenotypes:
      - preferred_term: Optic atrophy
        term:
          id: HP:0000648
          label: Optic atrophy
      - preferred_term: Peripheral neuropathy
        term:
          id: HP:0009830
          label: Peripheral neuropathy
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          AAV-Fdxr treatment reversed almost all the symptoms of the mutants
          (Fdxr R389Q/R389Q ). This therapy also improved the electronic conductivity
          of the sciatic nerves, prevented optic atrophy, improved mobility, and
          restored mitochondrial complex function.
        explanation: >
          First demonstration of AAV gene therapy efficacy in Fdxr mutant mice.
  - name: Omaveloxolone (Preclinical)
    description: >
      NRF2 activator (FDA-approved for Friedreich's ataxia) shown to mitigate ferroptotic
      pathogenesis in FDXR mouse model and cells. Administration reduced lipid peroxidation
      and ferroptosis susceptibility caused by NRF2/SLC7A11 pathway disruption.
      Proposed as an immediate, viable treatment option for FDXR-related disease and
      other conditions involving aberrant iron metabolism. No human trials for MMDS9B
      as of 2025.
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      therapeutic_agent:
        - preferred_term: omaveloxolone
          term:
            id: CHEBI:229661
            label: omaveloxolone
    target_mechanisms:
      - target: Ferroptosis via NRF2 Pathway Disruption
        treatment_effect: INHIBITS
        description: >
          Omaveloxolone activates NRF2 and mitigates the ferroptotic FDXR disease
          mechanism in the preclinical model.
        evidence:
          - reference: DOI:10.1038/s41420-025-02840-y
            reference_title: "Ferroptosis is a novel pathogenic mechanism of FDXR-related disease via disruption of the NRF2 pathway"
            supports: SUPPORT
            evidence_source: MODEL_ORGANISM
            snippet: >
              administration of the NRF2 activator omaveloxolone , which was recently
              approved by the FDA for treatment of Friedreich’s ataxia, helps mitigate
              the pathogenesis.
            explanation: >
              The preclinical study supports omaveloxolone as an NRF2-activating
              inhibitor/modulator of the ferroptotic pathogenesis.
    evidence:
      - reference: DOI:10.1038/s41420-025-02840-y
        reference_title: "Ferroptosis is a novel pathogenic mechanism of FDXR-related disease via disruption of the NRF2 pathway"
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          administration of the NRF2 activator omaveloxolone , which was recently
          approved by the FDA for treatment of Friedreich’s ataxia, helps mitigate
          the pathogenesis.
        explanation: >
          Preclinical evidence for omaveloxolone as an NRF2-activating therapeutic
          strategy in FDXR-related disease.
  - name: Genetic Counseling
    description: >
      Essential for all affected families. Autosomal recessive inheritance with 25%
      recurrence risk per pregnancy for carrier parents. Carrier testing available for
      at-risk relatives. Carrier screening for p.Arg386Trp proposed for Mexican/Hispanic
      populations, meeting all standard criteria (significant QoL impact, high carrier
      frequency, valid test, established genotype-phenotype correlation). Reproductive
      options include PGT, prenatal diagnosis (CVS/amniocentesis), and donor gametes.
      Cascade genetic testing recommended for siblings and extended family.
    treatment_term:
      preferred_term: genetic counseling
      term:
        id: MAXO:0000079
        label: genetic counseling
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          consideration of a new approach for population carrier screening and
          development of therapeutics for affected individuals is needed.
        explanation: >
          Recommends carrier screening in Mexican population based on high carrier frequency.
  - name: Physical Therapy and Rehabilitation
    description: >
      Physical therapy for motor deficits from ataxia, neuropathy, and hypotonia.
      Occupational therapy for adaptive skills in setting of visual and motor impairment.
      Speech therapy if developmental delay affects communication. Orientation and
      mobility training for visual impairment.
    treatment_term:
      preferred_term: physical therapy
      term:
        id: MAXO:0000011
        label: physical therapy
  - name: Vaccination (Preventive)
    description: >
      Standard childhood immunization schedule should be followed. Since intercurrent
      infections may trigger neurological deterioration, maintaining up-to-date
      vaccinations is especially important to prevent vaccine-preventable infections.
    treatment_term:
      preferred_term: vaccination
      term:
        id: MAXO:0001017
        label: vaccination
diagnosis:
  - name: Whole Exome Sequencing
    description: >
      Primary diagnostic tool. Identifies biallelic pathogenic variants in FDXR.
      Gene panel testing including FDXR and mitochondrial disease panels are also
      appropriate first-line genetic tests.
    evidence:
      - reference: PMID:29040572
        reference_title: "Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          we conducted whole-exome sequencing of patients with optic atrophy and other
          neurological signs of mitochondriopathy and identified 17 individuals from
          13 unrelated families with recessive mutations in FDXR
        explanation: WES was the primary diagnostic tool in the original cohort.
  - name: Ophthalmological Examination
    description: >
      Fundoscopy reveals pale optic discs and retinal dystrophy with attenuated vessels.
      Fundus fluorescein angiography (FFA) may reveal retinal vascular occlusion as a
      distinct clinical characteristic. Optical coherence tomography (OCT) can measure
      retinal nerve fiber layer thickness as a progression biomarker.
    evidence:
      - reference: PMID:37481223
        reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          Retinal dystrophy with attenuated retinal vessels appearing as white lines was
          observed in this cohort, and the FFA images revealed that retinal vascular
          occlusion could be a distinct clinical characteristic
        explanation: >
          Documents distinct ophthalmological findings useful for diagnosis.
  - name: Electroretinogram
    description: >
      ERG shows severely impaired cone and rod functions, supporting diagnosis of
      FDXR-associated retinal dystrophy.
    evidence:
      - reference: PMID:37481223
        reference_title: "FDXR-associated disease in a Chinese cohort: Unraveling expanded ocular phenotypes and genetic spectrum."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          electroretinogram showed severely impaired cone and rod functions in their
          first decades
        explanation: ERG findings support diagnosis of FDXR-associated retinal dystrophy.
  - name: Brain MRI
    description: >
      May show bilateral symmetric basal ganglia signal abnormalities (Leigh syndrome
      pattern), cerebellar atrophy, cerebral atrophy, and optic nerve thinning. The
      pattern correlates with disease severity: Leigh syndrome features suggest severe
      early-onset, while isolated cerebellar atrophy is seen in milder cases.
  - name: Nerve Conduction Studies and EMG
    description: >
      Nerve conduction velocity (NCV) and electromyography (EMG) reveal sensorimotor
      peripheral neuropathy with demyelinating and/or axonal features. Important for
      documenting peripheral neuropathy severity and distinguishing from inflammatory
      neuropathies.
  - name: Auditory Brainstem Response
    description: >
      ABR testing documents auditory neuropathy. Important for early detection of
      hearing loss and determining candidacy for cochlear implantation.
  - name: Mitochondrial Enzyme Testing
    description: >
      Measurement of mitochondrial respiratory chain enzyme activities in muscle biopsy
      or fibroblasts. May show deficiency of complexes I, II, III, and/or IV. Not always
      abnormal, especially in fibroblasts. Standard metabolic workup is often normal.
  - name: Yeast Functional Assay
    description: >
      Arh1-null yeast complementation assay for rapid functional classification of
      FDXR variants of uncertain significance (VUS). Bypasses the requirement for
      patient-derived material.
    evidence:
      - reference: PMID:33348459
        reference_title: "Expanding the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of uncertain significance."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          Here we implement an Arh1-null yeast model to confirm the pathogenicity of
          variants of uncertain significance in FDXR, bypassing the requirement for
          patient-derived material.
        explanation: >
          Yeast complementation assay validates FDXR VUS without needing patient samples.
  - name: Clinical Diagnostic Criteria
    description: >
      No formal diagnostic criteria published. Clinical suspicion should be raised by
      the combination of progressive optic atrophy, sensorineural hearing loss, ataxia
      or neuropathy, onset in childhood, and autosomal recessive inheritance. Confirmed
      by identification of biallelic pathogenic FDXR variants on WES or gene panel.
  - name: Carrier Screening
    description: >
      Carrier screening for p.Arg386Trp proposed for Mexican/Hispanic populations.
      Meets all standard screening criteria: significant QoL impact, high carrier
      frequency (1:185), valid methodology, established genotype-phenotype correlation.
      Cascade testing recommended for at-risk family members once familial variants are
      known. Not currently included in standard newborn screening panels due to lack of
      a reliable biochemical biomarker.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          the carrier frequency of the p.Arg386Trp variant was estimated as 1 of 185
          in the Mexican population.
        explanation: High carrier frequency supporting population-based screening proposal.
differential_diagnoses:
  - name: Leber Hereditary Optic Neuropathy
    description: >
      LHON shares optic atrophy but is caused by mitochondrial DNA mutations and
      typically has acute/subacute onset in young adults. mtDNA testing rules out LHON.
  - name: Friedreich Ataxia
    description: >
      Shares ataxia, neuropathy, and iron dysregulation but is caused by GAA repeat
      expansion in FXN and has characteristic cardiac involvement. Repeat expansion
      testing distinguishes the two.
  - name: Chronic Inflammatory Demyelinating Polyneuropathy
    description: >
      FDXR disease can mimic CIDP at onset. Genetic testing distinguishes the two
      conditions.
    evidence:
      - reference: PMID:37046037
        reference_title: "FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          a peripheral neuropathy which can mimic an acute inflammatory disease
        explanation: FDXR disease can closely mimic inflammatory neuropathy.
  - name: Other MMDS Subtypes
    description: >
      MMDS types 1-10 caused by variants in ISCA1, ISCA2, NFU1, BOLA3, IBA57, FDX2,
      and other iron-sulfur cluster assembly genes share overlapping features.
  - name: Leigh Syndrome (Other Causes)
    description: >
      Severe early-onset MMDS9B can present as Leigh syndrome, requiring genetic testing
      to distinguish from other causes (>75 genes known to cause Leigh syndrome).
    evidence:
      - reference: PMID:33348459
        reference_title: "Expanding the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of uncertain significance."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          These patients show a broad clinical spectrum ranging from Leigh syndrome with
          early demise and severe infantile-onset encephalopathy, to milder movement
          disorders.
        explanation: FDXR deficiency can present as Leigh syndrome.
  - name: Charcot-Marie-Tooth Disease
    description: >
      Hereditary peripheral neuropathy that shares sensorimotor neuropathy features
      with MMDS9B. Distinguished by absence of optic atrophy and auditory neuropathy,
      and by genetic testing.
  - name: Congenital Retinal Dystrophy
    description: >
      Leber congenital amaurosis and other inherited retinal dystrophies share
      retinal findings but lack the progressive neurological features of MMDS9B.
animal_models:
  - species: Mouse
    genotype: Fdxr(R389Q/R389Q)
    background: B6/129S
    description: >
      Spontaneous/naturally occurring homozygous mouse mutant carrying the p.Arg389Gln
      variant, affecting the corresponding residue (human Arg392) but with a different
      amino acid substitution (Gln vs Trp). Closely recapitulates human disease with
      progressive optic atrophy (54% retinal ganglion cell loss at 6 months), peripheral
      neuropathy (reduced sciatic nerve conduction), ataxia (rotarod and Morris Water
      Maze failure), neurodegeneration with gliosis (hippocampus, cerebellum, cortex),
      and mitochondrial complex I and III deficiencies. FDXR activity 33-49% of
      wild-type. Shorter lifespan and spontaneous tumors. Used for preclinical AAV gene
      therapy studies. Limitations: seizures not prominently reported, hearing loss not
      characterized, infection-triggered deterioration not studied, single homozygous
      variant does not model compound heterozygous genotypes.
    associated_phenotypes:
      - Progressive vision loss
      - Optic nerve demyelination
      - Sensory neuropathy
      - Gait abnormalities
      - Brain neurodegeneration
      - Mitochondrial complex I and III deficiency
      - Spontaneous tumors
    evidence:
      - reference: PMID:32995353
        reference_title: "Systemic Delivery of AAV-Fdxr Mitigates the Phenotypes of Mitochondrial Disorders in Fdxr Mutant Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          we have utilized a mouse model carrying a p.Arg389Gln mutation of the
          mitochondrial Ferredoxin Reductase gene (Fdxr) and treated them with
          neurotropic AAV-PHP.B vector loaded with the mouse Fdxr cDNA sequence
        explanation: >
          Describes the Fdxr mouse model used for gene therapy studies.
      - reference: PMID:30250212
        reference_title: "Biallelic mutations in FDXR cause neurodegeneration associated with inflammation."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          We found that Fdxr mutant mouse brain tissues share pathological changes
          similar to those seen in patient autopsy material, including increased astrocytes.
        explanation: >
          Documents neurodegeneration and gliosis in Fdxr mutant mice matching human pathology.
  - species: Saccharomyces cerevisiae
    genotype: Arh1-null
    description: >
      Yeast model with deletion of ARH1, the FDXR ortholog (systematic name YDR376W).
      Used for rapid functional validation of human FDXR variants of uncertain
      significance through complementation assay. Recapitulates iron-sulfur cluster
      assembly deficiency but not neurological features. FDXR is highly conserved
      across eukaryotes; human FDXR can functionally replace yeast ARH1.
    associated_phenotypes:
      - Iron-sulfur cluster assembly deficiency
    evidence:
      - reference: PMID:33348459
        reference_title: "Expanding the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of uncertain significance."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >
          Here we implement an Arh1-null yeast model to confirm the pathogenicity of
          variants of uncertain significance in FDXR
        explanation: Yeast complementation model for variant classification.
  - species: Equus caballus
    genotype: FDXR cryptic exon in intron 2
    background: Quarter Horse (VBO:0001057)
    description: >
      Naturally occurring autosomal recessive neurological disease in Quarter Horses
      (VBO:0001057), termed Equine Juvenile Spinocerebellar Ataxia (EJSCA). Affected
      foals develop progressive proprioceptive ataxia by 1-5 weeks of age with rapid
      progression to recumbency (median 3 days from onset), uniformly fatal, necessitating
      humane euthanasia. Lesions confined to the dorsal spinocerebellar tract with
      Wallerian-type degeneration. Clinicopathological abnormalities include elevated GGT
      and hyperglycemia. High veterinary relevance for breeding decisions. Demonstrates
      cross-species conservation of FDXR-related neurodegeneration. Clinically
      characterized by Willis et al. 2024; the FDXR genetic cause (intronic variant
      inducing a cryptic exon in intron 2) was subsequently identified by Brown et al.
      2025 (doi:10.1016/j.jevs.2025.105561, no PMID available).
    associated_phenotypes:
      - Progressive proprioceptive ataxia
      - Asymmetrical spinal ataxia
      - Dorsal spinocerebellar tract degeneration
      - Elevated serum GGT
      - Hyperglycemia
    evidence:
      - reference: PMID:38669583
        reference_title: "Clinicopathological and pedigree investigation of a novel spinocerebellar neurological disease in juvenile Quarter Horses in North America."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >
          EJSCA is a uniformly fatal, rapidly progressive, likely autosomal recessive
          neurological disease of QHs <1 month of age in North America that is
          etiologically distinct from other clinically similar neurological disorders.
        explanation: >
          Clinical and pathological characterization of EJSCA in Quarter Horses. The
          FDXR genetic cause was subsequently identified by Brown et al. 2025
          (doi:10.1016/j.jevs.2025.105561, no PMID available).
epidemiology:
  - name: Global Prevalence
    description: >
      Ultra-rare. Approximately 62 cases reported worldwide as of 2024 across multiple
      ethnic groups including European, Chinese, and Mexican/Hispanic populations. Not
      tracked in national mortality databases due to ultra-rare status and lack of
      specific ICD code.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          a natural history study of FRM was performed. New cases were added to previously
          reported FRM cases for analysis (n = 62 cases).
        explanation: Most comprehensive case count from the 2024 natural history study.
  - name: Mexican/Hispanic Population Carrier Frequency
    description: >
      The p.Arg386Trp hotspot variant has an estimated carrier frequency of 1:185 in the
      Mexican population. This variant accounts for ~25% of all reported cases. All but
      one individual heterozygous for this variant was Hispanic with many reporting
      Mexican heritage.
    evidence:
      - reference: PMID:39669623
        reference_title: "Clinical study of ferredoxin-reductase-related mitochondriopathy: Genotype-phenotype correlation and proposal of ancestry-based carrier screening in the Mexican population."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >
          the carrier frequency of the p.Arg386Trp variant was estimated as 1 of 185
          in the Mexican population.
        explanation: Carrier frequency data supporting targeted screening.
  - name: Geographic Distribution
    description: >
      Cases reported across multiple continents including Europe, Asia (Chinese families),
      and North America (Mexican/Hispanic heritage). No large patient registries exist.
      Disease-level data aggregated from approximately 62 published cases in literature.
  - name: Age Distribution
    description: >
      Bimodal distribution. Severe early-onset cases present in infancy (neonatal to
      infantile). Classic cases present in early childhood. Late-onset cases may present
      into the second decade. No sex predilection has been established.
  - name: High-Risk Populations
    description: >
      Siblings of affected individuals (25% recurrence risk). Children of consanguineous
      parents from populations with higher carrier frequency. Mexican/indigenous Mexican
      families (1:185 carrier frequency for p.Arg386Trp). Families with unexplained
      optic atrophy or auditory neuropathy.
notes: >
  MMDS9B is allelic to Auditory Neuropathy and Optic Atrophy (ANOA, OMIM #617717),
  representing a more severe end of the FDXR disease spectrum. The identification
  of naturally occurring FDXR disease in Quarter Horses (EJSCA) demonstrates
  remarkable cross-species conservation of FDXR-related neurodegeneration pathways.
  No disease-specific ICD-10 code exists; E88.8 (other specified metabolic disorders)
  is used. Gene therapy in the mouse model represents the most promising potential
  therapeutic approach. For affected individuals, avoidance of prolonged fasting and
  extreme metabolic stress is recommended. Prompt treatment of infections is important
  to prevent deterioration episodes. Awareness campaigns among pediatric neurologists
  and ophthalmologists to consider FDXR-related disease in the differential diagnosis
  of childhood optic atrophy have been proposed. Population carrier screening programs
  for Mexican/Hispanic communities and inclusion of FDXR in expanded carrier screening
  panels are recommended.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 23 citations 2026-04-03T08:30:10.819641

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Multiple Mitochondrial Dysfunctions Syndrome 9B
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on Multiple Mitochondrial Dysfunctions Syndrome 9B covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Multiple Mitochondrial Dysfunctions Syndrome 9B (MMDS9B)

Executive summary

Multiple mitochondrial dysfunctions syndrome 9B (MMDS9B) is an autosomal recessive primary mitochondrial disease caused by biallelic variants in FDXR (ferredoxin–NADP(+) reductase/ferredoxin reductase). The contemporary clinical framing in 2023–2024 literature is “FDXR-related mitochondriopathy (FRM)” or “FDXR-associated disease”, with prominent optic neuropathy/optic atrophy, variable auditory neuropathy/hearing loss, ataxia, and sensorimotor peripheral neuropathy, often with infection-triggered exacerbations. A 2024 mechanistic-clinical study expanded the phenotype to include adrenal insufficiency and disorders of sexual development in severe early-onset cases, consistent with FDXR’s role in mitochondrial P450 electron transfer for steroidogenesis. (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)

Domain	Key facts
Disease / synonyms	Multiple mitochondrial dysfunctions syndrome 9B (MMDS9B); FDXR-related mitochondriopathy (FRM); FDXR-associated disease; ocular presentations include FDXR-associated oculopathy, autosomal recessive optic atrophy with auditory neuropathy, congenital amaurosis/LCA-like disease, and early-onset severe retinal dystrophy (2023-2024) (yi2023fdxrassociatedoculopathycongenital pages 1-2, pignatti2024fdxrvariantscause pages 2-3)
Identifier(s)	MONDO: MONDO_0971174; gene OMIM: FDXR OMIM 103270; phenotype label reported in literature: autosomal recessive optic atrophy and auditory neuropathy (ANOA), OMIM 617717 (2023) (yi2023fdxrassociatedoculopathycongenital pages 1-2)
Causal gene / biology	FDXR encodes mitochondrial ferredoxin reductase / ferredoxin-NADP(+) reductase, supporting electron transfer from NADPH to ferredoxin and linked to iron-sulfur (Fe-S) cluster biogenesis, mitochondrial respiration, redox balance, and steroidogenic mitochondrial P450 systems (2023-2024) (yi2023fdxrassociatedoculopathycongenital pages 1-2, pignatti2024fdxrvariantscause pages 2-3)
Inheritance	Autosomal recessive / biallelic pathogenic or likely pathogenic FDXR variants; reported cohorts include 44 patients (2023 review) and 77 patients with 59 biallelic mutations (2024 review) (masnada2023fdxrassociateddiseasea pages 1-2, pignatti2024fdxrvariantscause pages 2-3)
Hallmark phenotypes	Common core phenotype: optic neuropathy/optic atrophy, auditory neuropathy/hearing loss, developmental delay/regression, hypotonia, pyramidal/cerebellar signs, neuropathy, retinal degeneration, seizures; ocular triad in some patients: optic disc pallor + attenuated/silver-wiring retinal vessels + generalized retinal degeneration (2023) (masnada2023fdxrassociateddiseasea pages 4-5, yi2023fdxrassociatedoculopathycongenital pages 9-10, yi2023fdxrassociatedoculopathycongenital pages 1-2)
Phenotype frequencies	Review data: optic neuropathy 93.2-93.5%, auditory/acoustic neuropathy 50.0%, ataxia 40.9-43.9%, sensorimotor peripheral polyneuropathy ~20.5-23.9% (22.72% in one review summary), retinal dystrophy 29.5%, nystagmus 18.2%, microcephaly 15.9%, movement disorders 13.6%, seizures 6.8% (2023) (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 2-4, masnada2023fdxrassociateddiseasea pages 1-2)
Ocular presentation details	In one 2023 Chinese cohort, 11 unrelated patients with biallelic FDXR variants had 4 congenital amaurosis/LCA-like and 7 EOSRD presentations; literature summary cited 42 optic atrophy and 24 retinal dystrophy cases, with 18 nystagmus cases (2023) (yi2023fdxrassociatedoculopathycongenital pages 1-2, yi2023fdxrassociatedoculopathycongenital pages 9-10, yi2023fdxrassociatedoculopathycongenital pages 2-5)
Onset / course / triggers	Often infantile or early-childhood onset, but presentations can be acute-subacute; some cases first mimic inflammatory neuropathy. Infection-triggered worsening/relapses are important: 15/44 (34%) had infection-associated relapses; 2024 review noted 20/77 (26%) severe, often life-threatening events/deadly infections and 12 deaths between 0.5-6 years (2023-2024) (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)
Pathophysiology	Current model links FDXR loss to defective Fe-S protein maturation, impaired oxidative phosphorylation/respiratory chain function, mitochondrial iron accumulation, excess ROS/lipid peroxidation, and tissue injury in retina, optic nerve, peripheral nerve, brain, adrenal and other high-energy tissues; 2025 preclinical work adds ferroptosis via NRF2/SLC7A11 disruption (2023-2025) (masnada2023fdxrassociateddiseasea pages 1-2, campbell2025ferroptosisisa pages 11-11, tanaka2025hepaticferredoxinreductase pages 1-5)
Diagnostic modalities	Diagnosis relies on genetic sequencing (WES/trio-WES, increasingly WGS/panel-based testing), ACMG/AMP variant interpretation, and phenotype-guided workup. Key modalities: ophthalmic exam/fundus/ERG, brain/spine MRI, neurophysiology (NCS/EMG, BAEP/ABR, VEP, SEP), and broad metabolic/infectious/autoimmune testing, which may be unrevealing (2023-2025) (masnada2023fdxrassociateddiseasea pages 1-2, masnada2023fdxrassociateddiseasea pages 2-4, cao2025identificationofgenetic pages 16-16)
Imaging / electrophysiology clues	MRI may be normal early, or show optic nerve atrophy, basal ganglia T2 hyperintensities, cerebellar/cerebral atrophy, thin corpus callosum, delayed myelination, spinal cord atrophy, or posterior column signal changes. Nerve studies often suggest primary axonal impairment, sometimes with reversible conduction block (2023) (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 2-4)
Real-world management	No proven disease-specific standard therapy. Reported care includes mitochondrial supplements such as coenzyme Q10, riboflavin, thiamine, lipoic acid; supportive neurologic/ophthalmic/audiologic care; cochlear implantation may be used for auditory neuropathy in selected patients (2023-2025) (masnada2023fdxrassociateddiseasea pages 4-5, cao2025identificationofgenetic pages 16-16)
Misdiagnosis / empiric immunotherapy	Acute neuropathic presentations may be misdiagnosed as inflammatory neuropathy; reported empiric treatments include IV methylprednisolone, IVIG, oral prednisone, azathioprine, with partial, transient, or unclear benefit and no established efficacy for MMDS9B itself (2023) (masnada2023fdxrassociateddiseasea pages 1-2, masnada2023fdxrassociateddiseasea pages 2-4)
Emerging / experimental therapeutics	AAV-Fdxr gene therapy improved optic atrophy, sensory neuropathy, and mitochondrial dysfunction in an Fdxr mouse model; omaveloxolone (an NRF2 activator) reduced ferroptotic features in a 2025 preclinical Fdxr mouse/cell model; authors also discuss antioxidants/iron-directed strategies as future avenues (2023-2025) (yi2023fdxrassociatedoculopathycongenital pages 9-10, campbell2025ferroptosisisa pages 11-11, yi2023fdxrassociatedoculopathycongenital pages 10-11)

Table: This table compiles the main identifiers, genetics, clinical features, diagnostics, and emerging therapeutic concepts for MMDS9B/FDXR-related mitochondriopathy. It is designed as a quick-reference summary for a disease knowledge base entry, with context-ID citations for each major claim.

1. Disease information

1.1 Definition and overview

MMDS9B (as used in disease ontologies) corresponds to FDXR-associated disease/FDXR-related mitochondriopathy (FRM), a rare recessive mitochondriopathy due to biallelic FDXR variants, with neuro-ophthalmologic and neurodegenerative phenotypes and variable systemic involvement. (masnada2023fdxrassociateddiseasea pages 1-2, pignatti2024fdxrvariantscause pages 2-3)

Recent abstract-supported definition (direct quote): Masnada et al. (2023) describe: “Mutations in FDXR gene, involved in mitochondrial pathway, cause a rare recessive neurological disorder with variable severity of phenotypes. The most common presentation includes optic and/or auditory neuropathy…” (Neurological Sciences, April 2023; https://doi.org/10.1007/s10072-023-06790-0). (masnada2023fdxrassociateddiseasea pages 1-2)

1.2 Key identifiers

MONDO: MONDO_0971174 (“multiple mitochondrial dysfunctions syndrome 9b”) (from OpenTargets disease object). (masnada2023fdxrassociateddiseasea pages 1-2)
Gene (OMIM): FDXR OMIM 103270. (yi2023fdxrassociatedoculopathycongenital pages 1-2)
Related phenotype label in OMIM (as used in ophthalmic genetics literature): Autosomal recessive optic atrophy and auditory neuropathy (ANOA), OMIM 617717. (yi2023fdxrassociatedoculopathycongenital pages 1-2)

Not found in retrieved texts: Orphanet disease identifier, ICD-10/ICD-11, and MeSH terms were not explicitly stated in the retrieved full-text excerpts, although an Orphanet gene page for FDXR is referenced in later literature. (tafakhori2026homozygousfdxrvariant pages 6-6)

1.3 Synonyms / alternative names used in the literature

FDXR-related mitochondriopathy (FRM) (2024). (pignatti2024fdxrvariantscause pages 2-3)
FDXR-associated disease (2023). (masnada2023fdxrassociateddiseasea pages 1-2)
Ophthalmology-facing labels (phenotype-first): FDXR-associated oculopathy, congenital amaurosis/Leber congenital amaurosis-like, early-onset severe retinal dystrophy (EOSRD). (yi2023fdxrassociatedoculopathycongenital pages 1-2, yi2023fdxrassociatedoculopathycongenital pages 2-5)

1.4 Evidence source type

Most disease knowledge is derived from aggregated literature case reports/series plus systematic reviews, rather than EHR-scale observational cohorts, reflecting the disorder’s rarity. The 2023 neurologic paper includes a systematic review; the 2024 JCI Insight paper includes case descriptions plus patient-derived functional models. (masnada2023fdxrassociateddiseasea pages 1-2, pignatti2024fdxrvariantscause pages 2-3)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in FDXR (autosomal recessive). (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)

Functional role of FDXR: FDXR is described as mitochondrial ferredoxin–NADP(+) reductase, transferring reducing equivalents from NADPH via ferredoxin to mitochondrial cytochrome P450 enzymes (steroid biosynthesis) and linked to mitochondrial redox/iron–sulfur biology. (yi2023fdxrassociatedoculopathycongenital pages 1-2, pignatti2024fdxrvariantscause pages 2-3)

Direct abstract-supported statement (direct quote): Pignatti et al. (JCI Insight, June 2024; https://doi.org/10.1172/jci.insight.179071) note: “FDXR is characterized as the mitochondrial flavoprotein ferredoxin–NADP(+) reductase that accepts electrons from NADPH and transfers them via ferredoxin (FDX) to mitochondrial cytochrome P450 enzymes” and frame disease as “FDXR-related mitochondriopathy (FRM)”. (pignatti2024fdxrvariantscause pages 2-3)

2.2 Risk factors

Genetic: autosomal recessive inheritance; consanguinity can be relevant in individual families. Masnada et al. report a consanguineous family with homozygous c.463C>T (p.Arg155Trp). (masnada2023fdxrassociateddiseasea pages 2-4)
Clinical trigger / modifier: infections frequently precipitate worsening/relapses (see §8). (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)

2.3 Protective factors

No established genetic or environmental protective factors were identified in the retrieved sources.

2.4 Gene–environment interactions

The ocular cohort review discusses that phenotype variability may be influenced by environmental/epigenetic and maternal factors in addition to variant pathogenicity, but specific validated gene–environment interaction mechanisms are not established. (yi2023fdxrassociatedoculopathycongenital pages 9-10)

3. Phenotypes

3.1 Core clinical phenotype spectrum (with frequencies from 2023 systematic review)

Masnada et al. summarize 44 patients from 35 families and provide phenotype frequencies, including: * Optic neuropathy/optic atrophy: ~93%. (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 2-4) * Auditory/acoustic neuropathy: 50%. (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 2-4) * Ataxia: ~41–44%. (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 1-2) * Sensorimotor peripheral polyneuropathy: ~20–24%. (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 1-2) * Retinal dystrophy: 29.5%. (masnada2023fdxrassociateddiseasea pages 2-4) * Nystagmus: 18.2%. (masnada2023fdxrassociateddiseasea pages 2-4) * Seizures: 6.8%. (masnada2023fdxrassociateddiseasea pages 2-4)

Other recurrent features include hypotonia, pyramidal signs, microcephaly, and movement disorders. (masnada2023fdxrassociateddiseasea pages 2-4)

Direct abstract-supported statistics (direct quote): Masnada et al. (2023) state their literature review found “a significant incidence of sensorimotor peripheral polyneuropathy (22.72%) and ataxia (43.18%)”. (masnada2023fdxrassociateddiseasea pages 1-2)

3.2 Ophthalmic phenotypes and real-world clinical presentation

A 2023 ophthalmic genetics cohort (Yi et al., Genes, April 2023; https://doi.org/10.3390/genes14040952) shows that biallelic FDXR variants are a frequent cause of congenital/early-onset severe retinal dystrophy in a Chinese WES dataset: * 11 unrelated patients were identified in a WES dataset of 6397 families with eye conditions. (yi2023fdxrassociatedoculopathycongenital pages 1-2) * Presentations included 4 with congenital amaurosis/LCA-like onset and 7 with EOSRD. (yi2023fdxrassociatedoculopathycongenital pages 1-2, yi2023fdxrassociatedoculopathycongenital pages 5-6) * A characteristic fundus “triad” described includes optic disc pallor, silver-wiring/attenuated retinal vessels, and generalized retinal degeneration, supported visually in the paper’s figures and tables. (yi2023fdxrassociatedoculopathycongenital pages 9-10, yi2023fdxrassociatedoculopathycongenital media 63ac4024)

3.3 Suggested HPO terms (non-exhaustive; mapped to reported features)

Optic atrophy / optic neuropathy: HP:0000648
Retinal dystrophy: HP:0000556
Nystagmus: HP:0000639
Auditory neuropathy / sensorineural hearing impairment: HP:0000407 (hearing impairment); HP:0008619 (auditory neuropathy; if using more specific term)
Peripheral neuropathy: HP:0000759
Ataxia: HP:0001251
Hypotonia: HP:0001252
Seizures: HP:0001250
Developmental delay / regression: HP:0001263 / HP:0002376
Pyramidal signs / spasticity: HP:0001257
Microcephaly: HP:0000252

3.4 Laboratory/biochemical abnormalities (clinical-level)

Routine metabolic/infectious/autoimmune testing may be unrevealing in some patients, contributing to diagnostic delay and misdiagnosis as inflammatory neuropathy. (masnada2023fdxrassociateddiseasea pages 2-4)

4. Genetic / molecular information

4.1 Causal gene

Gene: FDXR (ferredoxin reductase / ferredoxin–NADP(+) reductase), OMIM 103270. (yi2023fdxrassociatedoculopathycongenital pages 1-2)

4.2 Pathogenic variants and variant spectrum

Predominantly biallelic missense variants are reported across cohorts; Yi et al. found 14 missense variants among 11 unrelated patients, 10 novel, with ACMG/AMP classifications including pathogenic and likely pathogenic. (yi2023fdxrassociatedoculopathycongenital pages 1-2, yi2023fdxrassociatedoculopathycongenital pages 2-5)
A hotspot severe-phenotype variant p.R386W is referenced in the 2024 review. (pignatti2024fdxrvariantscause pages 2-3)
Example family-level variant with population-frequency annotation: c.463C>T (p.Arg155Trp) with gnomAD MAF noted in Masnada et al. (2023). (masnada2023fdxrassociateddiseasea pages 2-4)

4.3 Functional consequences

Evidence across clinical and mechanistic studies supports that FDXR variants lead to impaired mitochondrial electron transfer (NADPH→FDX), mitochondrial dysfunction, and—in severe cases—impaired steroidogenesis consistent with disrupted mitochondrial P450 enzyme function. (pignatti2024fdxrvariantscause pages 2-3)

4.4 Modifier genes / epigenetics

No validated modifier genes were identified in retrieved sources. Phenotypic variability is noted and hypothesized to involve non-genetic modifiers, but specific epigenetic mechanisms are not established. (yi2023fdxrassociatedoculopathycongenital pages 9-10)

5. Environmental information

No specific environmental toxins, lifestyle factors, or infectious agents are identified as primary causes. Infections are described as clinical triggers for relapse/worsening rather than etiologic agents. (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)

6. Mechanism / pathophysiology

6.1 Current mechanistic understanding (2023–2025 synthesis)

A coherent mechanistic chain supported by recent clinical-functional and preclinical work is: 1. Upstream defect: biallelic FDXR loss-of-function or functional impairment reduces electron transfer from NADPH through FDXR/ferredoxin to (a) mitochondrial Fe–S/iron/redox systems and (b) mitochondrial cytochrome P450 enzymes. (pignatti2024fdxrvariantscause pages 2-3) 2. Downstream mitochondrial consequences: mitochondrial dysfunction with oxidative stress and dysregulated iron handling, leading to tissue vulnerability in high-energy systems (retina/optic nerve, peripheral nerve, brain; and adrenal in severe cases). (masnada2023fdxrassociateddiseasea pages 1-2, tanaka2025hepaticferredoxinreductase pages 1-5) 3. Emerging cell-death mechanism: a 2025 mechanistic study proposes that FDXR loss increases lipid peroxidation and susceptibility to ferroptosis via disrupted NRF2 pathway and SLC7A11, and demonstrates rescue of ferroptotic features with an NRF2 activator. (campbell2025ferroptosisisa pages 11-11)

6.2 Expert interpretations / authoritative analyses

Clinical expert synthesis (2023): emphasizes a broad neurodegenerative phenotype with frequent optic/auditory neuropathy and clinically important peripheral neuropathy that can mimic inflammatory disorders. (masnada2023fdxrassociateddiseasea pages 1-2, masnada2023fdxrassociateddiseasea pages 4-5)
Mechanistic clinical expansion (2024, JCI Insight): links FDXR dysfunction to steroidogenesis and documents adrenal insufficiency/DSD phenotypes, explaining clinical deterioration under stress/infection in some patients as potentially compounded by adrenal insufficiency. (pignatti2024fdxrvariantscause pages 2-3)
Therapeutic mechanistic hypothesis (2025): positions NRF2 activation as an “immediate, viable treatment option” in preclinical context, while cautioning it may not address all enzymatic deficits intrinsic to FDXR loss. (campbell2025ferroptosisisa pages 11-11)

6.3 Suggested GO biological process terms (examples)

Iron–sulfur cluster assembly (GO:0016226)
Mitochondrial electron transport, NADH to ubiquinone (GO:0006120) (downstream OXPHOS impairment)
Response to oxidative stress (GO:0006979)
Steroid biosynthetic process (GO:0006694)
Regulation of ferroptosis (GO term exists; depending on ontology version)

6.4 Suggested CL cell types and GO cellular components

Retinal ganglion cell (CL:0000740) (optic neuropathy context)
Photoreceptor cell (CL:0000210) (retinal dystrophy context)
Peripheral neuron / Schwann cell (for neuropathy; exact CL terms depend on granularity)
Cellular component: mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743)

7. Anatomical structures affected

7.1 Primary organs/systems

Eye/visual system: optic nerve/retinal degeneration is a dominant feature (optic disc pallor, retinal vessel attenuation, generalized degeneration). (yi2023fdxrassociatedoculopathycongenital pages 9-10, yi2023fdxrassociatedoculopathycongenital media 63ac4024)
Auditory system: auditory neuropathy/hearing loss common. (masnada2023fdxrassociateddiseasea pages 4-5)
Central and peripheral nervous system: cerebellar/ataxic features and peripheral neuropathy (often axonal). (masnada2023fdxrassociateddiseasea pages 4-5)
Endocrine/adrenal system: adrenal insufficiency documented in severe FRM cases (2024). (pignatti2024fdxrvariantscause pages 2-3)

7.2 Suggested UBERON anatomical terms (examples)

Optic nerve: UBERON:0001890
Retina: UBERON:0000966
Cochlea / inner ear: UBERON:0001845
Peripheral nerve: UBERON:0001021
Adrenal gland: UBERON:0002369

8. Temporal development

8.1 Onset

Typical onset is infantile to early-childhood, though subacute presentations occur; ophthalmic onset can be within months (nystagmus and severe visual impairment), consistent with congenital amaurosis/EOSRD presentations. (yi2023fdxrassociatedoculopathycongenital pages 1-2, yi2023fdxrassociatedoculopathycongenital pages 5-6)

8.2 Progression and triggers

Infection-triggered relapses/worsening: Masnada et al. report infection-triggered relapses in 15/44 (34%). (masnada2023fdxrassociateddiseasea pages 4-5)
Severe early-life events and mortality: Pignatti et al. (2024) report that in their review 20/77 (26%) experienced severe, often life-threatening events/deadly infections, and 12 deaths occurred between 0.5–6 years, “mostly after infection”. (pignatti2024fdxrvariantscause pages 2-3)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive inheritance with biallelic pathogenic/likely pathogenic variants. (masnada2023fdxrassociateddiseasea pages 4-5, yi2023fdxrassociatedoculopathycongenital pages 2-5)

9.2 Epidemiology

No prevalence/incidence estimates were provided in the retrieved sources. Available quantitative disease frequency evidence is limited to case counts in the literature, including 44 reported patients summarized in 2023 and 77 summarized in 2024. (masnada2023fdxrassociateddiseasea pages 1-2, pignatti2024fdxrvariantscause pages 2-3)

9.3 Population genetics / variant frequencies

A specific variant example includes a gnomAD minor allele frequency annotation for p.Arg155Trp in Masnada et al. (2023), illustrating that some pathogenic alleles can be extremely rare but present in reference databases. (masnada2023fdxrassociateddiseasea pages 2-4)
In the 2023 Chinese ocular cohort, common alleles among identified mutant alleles included p.R79C, p.R104C, and p.V314L, with allele proportions reported within that cohort’s mutant allele set. (yi2023fdxrassociatedoculopathycongenital pages 2-5)

10. Diagnostics

10.1 Clinical tests and evaluations used in practice

Neurophysiology: NCS/EMG often shows axonal impairment; BAEP/ABR and VEP/SEP can be informative. (masnada2023fdxrassociateddiseasea pages 1-2, masnada2023fdxrassociateddiseasea pages 4-5)
Imaging: brain/spine MRI may be normal early, or show optic nerve atrophy and other neurodegenerative changes (e.g., cerebral/cerebellar atrophy, thin corpus callosum, delayed myelination, spinal cord/posterior column changes). (masnada2023fdxrassociateddiseasea pages 4-5, masnada2023fdxrassociateddiseasea pages 2-4)
Ophthalmic testing: fundus photography and ERG; characteristic fundus triad is visually documented in the 2023 Genes paper figures/tables. (yi2023fdxrassociatedoculopathycongenital media 63ac4024)

10.2 Genetic testing (recommended approach)

Trio-WES/WES is frequently diagnostic in published cases; ACMG/AMP interpretation is applied. (masnada2023fdxrassociateddiseasea pages 2-4, yi2023fdxrassociatedoculopathycongenital pages 2-5)
For phenotype-first ophthalmic cohorts (LCA/EOSRD), inclusion of FDXR in IRD/optic neuropathy panels or exome re-analysis is supported by 2023 cohort evidence. (yi2023fdxrassociatedoculopathycongenital pages 1-2)

10.3 Differential diagnosis

Inflammatory neuropathies (GBS/CIDP-like): acute/subacute peripheral neuropathy presentations can mimic inflammatory disease, leading to empiric immunotherapy and diagnostic delay. (masnada2023fdxrassociateddiseasea pages 1-2, masnada2023fdxrassociateddiseasea pages 2-4)
Inherited retinal dystrophies / hereditary optic neuropathies: broad genetic heterogeneity necessitates multigene testing; FDXR is among recurrent genes in optic neuropathy diagnostics. (yi2023fdxrassociatedoculopathycongenital pages 1-2)

11. Outcomes / prognosis

Prognosis is variable, spanning slowly progressive neuro-ophthalmologic disease to severe early-onset multisystem disease with fatal infection-associated deterioration in a subset. (masnada2023fdxrassociateddiseasea pages 4-5, pignatti2024fdxrvariantscause pages 2-3)

Quantitative outcomes reported in 2024 synthesis: 12 deaths between 0.5–6 years among the 77-patient literature summary, mostly after infection; 26% experienced severe life-threatening events/deadly infections. (pignatti2024fdxrvariantscause pages 2-3)

12. Treatment

12.1 Current real-world management

There is no established disease-specific therapy in the retrieved clinical literature. Reported management includes supportive and empiric interventions: * “Mitochondrial cocktails” such as coenzyme Q10, riboflavin, thiamine, lipoic acid are reported in cases/reviews. (masnada2023fdxrassociateddiseasea pages 4-5) * For patients misdiagnosed with inflammatory neuropathy, empiric IV methylprednisolone, IVIG, and longer immunosuppression were used with partial/uncertain benefit and no proven disease-modifying efficacy. (masnada2023fdxrassociateddiseasea pages 2-4)

12.2 Emerging / experimental therapeutics (preclinical)

Gene therapy: systemic AAV-Fdxr delivery improved optic atrophy, neuropathy, and mitochondrial dysfunction in an Fdxr mouse model, supporting feasibility of gene replacement strategies. (yi2023fdxrassociatedoculopathycongenital pages 10-11)
NRF2 activation (drug repurposing concept): a 2025 mechanistic study reports mitigation of ferroptotic features in an Fdxr model with omaveloxolone (NRF2 activator; FDA-approved for Friedreich’s ataxia), proposing NRF2 activation as a candidate approach (preclinical; not yet established clinically for FRM). (campbell2025ferroptosisisa pages 11-11)

12.3 Suggested MAXO terms (examples)

Supportive mitochondrial therapy: MAXO:0000781 (mitochondrial disease treatment; if available) / MAXO:0000646 (nutritional supplementation)
Genetic counseling: MAXO:0000075
Gene therapy: MAXO:0000127
Cochlear implantation (for auditory neuropathy in selected cases): MAXO:0000504

13. Prevention

Primary prevention is not applicable for an inherited recessive disorder beyond reproductive options. Practical prevention focuses on: * Genetic counseling for families and at-risk relatives. (yi2023fdxrassociatedoculopathycongenital pages 2-5) * Prenatal/embryo screening suggested for couples with an affected child (as stated in the 2023 ophthalmic cohort discussion). (yi2023fdxrassociatedoculopathycongenital pages 10-11)

14. Other species / natural disease

No naturally occurring veterinary disease analogs were identified in the retrieved sources.

15. Model organisms

Relevant models in 2023–2025 sources include: * Fdxr mouse models used for proof-of-concept systemic AAV gene therapy improving ocular/neurologic phenotypes and mitochondrial dysfunction. (yi2023fdxrassociatedoculopathycongenital pages 10-11) * CRISPR/Cas9-engineered Fdxr mutant mouse and corresponding cells used to test ferroptosis mechanism and pharmacologic rescue with omaveloxolone. (campbell2025ferroptosisisa pages 11-11) * Patient-derived fibroblasts reprogrammed to adrenal-like cell models to demonstrate impaired steroidogenesis from FDXR variants (mechanistic link to adrenal insufficiency). (pignatti2024fdxrvariantscause pages 2-3)

Notes on evidence gaps and constraints

The retrieved corpus did not include explicit ICD-10/ICD-11, Orphanet disease IDs, or MeSH identifiers for MMDS9B, and did not provide population prevalence/incidence estimates; the report therefore relies on case-series totals and systematic review summaries without extrapolating population metrics. (masnada2023fdxrassociateddiseasea pages 1-2, pignatti2024fdxrvariantscause pages 2-3)

References

(masnada2023fdxrassociateddiseasea pages 4-5): Silvia Masnada, Roberto Previtali, Paola Erba, Elena Beretta, Anna Camporesi, Luisa Chiapparini, Chiara Doneda, Maria Iascone, Marco U. A. Sartorio, Luigina Spaccini, Pierangelo Veggiotti, Maurizio Osio, Davide Tonduti, and Isabella Moroni. Fdxr-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy. Neurological Sciences, 44:1-7, Apr 2023. URL: https://doi.org/10.1007/s10072-023-06790-0, doi:10.1007/s10072-023-06790-0. This article has 8 citations and is from a peer-reviewed journal.
(pignatti2024fdxrvariantscause pages 2-3): Emanuele Pignatti, Jesse Slone, María Ángeles Gómez Cano, Teresa Margaret Campbell, Jimmy Vu, Kay Sauter, Amit Vikram Pandey, Francisco Martínez-Azorín, Marina Alonso-Riaño, Derek E Neilson, Nicola Longo, Therina du Toit, Clarissa Vögel, Taosheng Huang, and Christa Emma Flück Pandey. Fdxr variants cause adrenal insufficiency and atypical sexual development. JCI Insight, Jun 2024. URL: https://doi.org/10.1172/jci.insight.179071, doi:10.1172/jci.insight.179071. This article has 6 citations and is from a domain leading peer-reviewed journal.
(yi2023fdxrassociatedoculopathycongenital pages 1-2): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.
(masnada2023fdxrassociateddiseasea pages 1-2): Silvia Masnada, Roberto Previtali, Paola Erba, Elena Beretta, Anna Camporesi, Luisa Chiapparini, Chiara Doneda, Maria Iascone, Marco U. A. Sartorio, Luigina Spaccini, Pierangelo Veggiotti, Maurizio Osio, Davide Tonduti, and Isabella Moroni. Fdxr-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy. Neurological Sciences, 44:1-7, Apr 2023. URL: https://doi.org/10.1007/s10072-023-06790-0, doi:10.1007/s10072-023-06790-0. This article has 8 citations and is from a peer-reviewed journal.
(yi2023fdxrassociatedoculopathycongenital pages 9-10): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.
(masnada2023fdxrassociateddiseasea pages 2-4): Silvia Masnada, Roberto Previtali, Paola Erba, Elena Beretta, Anna Camporesi, Luisa Chiapparini, Chiara Doneda, Maria Iascone, Marco U. A. Sartorio, Luigina Spaccini, Pierangelo Veggiotti, Maurizio Osio, Davide Tonduti, and Isabella Moroni. Fdxr-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy. Neurological Sciences, 44:1-7, Apr 2023. URL: https://doi.org/10.1007/s10072-023-06790-0, doi:10.1007/s10072-023-06790-0. This article has 8 citations and is from a peer-reviewed journal.
(yi2023fdxrassociatedoculopathycongenital pages 2-5): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.
(campbell2025ferroptosisisa pages 11-11): Teresa Campbell, Jesse Slone, Jimmy Vu, Wensheng Liu, Li Yang, Adam Dourson, Luis F. Queme, Michael P. Jankowski, and Taosheng Huang. Ferroptosis is a novel pathogenic mechanism of fdxr-related disease via disruption of the nrf2 pathway. Cell Death Discovery, Dec 2025. URL: https://doi.org/10.1038/s41420-025-02840-y, doi:10.1038/s41420-025-02840-y. This article has 0 citations and is from a peer-reviewed journal.
(tanaka2025hepaticferredoxinreductase pages 1-5): Tomoaki Tanaka, Ikki Sakuma, Rafael Gaspar, Panu Luukkonen, Brandon Hubbard, Daniel Vatner, Ali Nasiri, Sylvie Dufour, Mario Kahn, Mark Perelis, Yuki Taki, Akitoshi Nakayama, Masanori Fujimoto, Takashi Kono, Takashi Miki, Koutaro Yokote, Kitt Petersen, Varman Samuel, and Gerald Shulman. Hepatic ferredoxin reductase modulates mitochondrial function and iron homeostasis in metabolic dysfunction-associated steatotic liver disease. Research Square, Aug 2025. URL: https://doi.org/10.21203/rs.3.rs-7014857/v1, doi:10.21203/rs.3.rs-7014857/v1. This article has 0 citations.
(cao2025identificationofgenetic pages 16-16): Yang Cao, Xiaolong Zhang, Lan Lan, Danyang Li, Jin Li, Linyi Xie, Fen Xiong, Lan Yu, Xiaonan Wu, Hongyang Wang, and Qiuju Wang. Identification of genetic mechanisms of non-isolated auditory neuropathy with various phenotypes in chinese families. Orphanet Journal of Rare Diseases, Jan 2025. URL: https://doi.org/10.1186/s13023-025-03540-7, doi:10.1186/s13023-025-03540-7. This article has 3 citations and is from a peer-reviewed journal.
(yi2023fdxrassociatedoculopathycongenital pages 10-11): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.
(tafakhori2026homozygousfdxrvariant pages 6-6): Abbas Tafakhori, Zahra Sarvestani, Ariana Kariminejad, Homa Tajsharghi, Go Hun Seo, Seung Woo Ryu, and Sanaz Heydari Havadaragh. Homozygous fdxr variant in twin sisters with spastic paraparesis followed by acute progressive flaccid quadriparesis. BMC Neurology, Feb 2026. URL: https://doi.org/10.1186/s12883-026-04752-5, doi:10.1186/s12883-026-04752-5. This article has 0 citations and is from a peer-reviewed journal.
(yi2023fdxrassociatedoculopathycongenital pages 5-6): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.
(yi2023fdxrassociatedoculopathycongenital media 63ac4024): Shutong Yi, Yuxiang Zheng, Zhen Yi, Yingwei Wang, Yi Jiang, Jiamin Ouyang, Shi-qiang Li, Xueshan Xiao, Wenmin Sun, Panfeng Wang, and Qingjiong Zhang. Fdxr-associated oculopathy: congenital amaurosis and early-onset severe retinal dystrophy as common presenting features in a chinese population. Genes, 14:952, Apr 2023. URL: https://doi.org/10.3390/genes14040952, doi:10.3390/genes14040952. This article has 11 citations.

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Biochemical Markers

Differential Diagnoses

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Comprehensive Research Report: Multiple Mitochondrial Dysfunctions Syndrome 9B (MMDS9B)

Executive summary

1. Disease information

1.1 Definition and overview

1.2 Key identifiers

1.3 Synonyms / alternative names used in the literature

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core clinical phenotype spectrum (with frequencies from 2023 systematic review)

3.2 Ophthalmic phenotypes and real-world clinical presentation

3.3 Suggested HPO terms (non-exhaustive; mapped to reported features)

3.4 Laboratory/biochemical abnormalities (clinical-level)

4. Genetic / molecular information

4.1 Causal gene

4.2 Pathogenic variants and variant spectrum

4.3 Functional consequences

4.4 Modifier genes / epigenetics

5. Environmental information

6. Mechanism / pathophysiology

6.1 Current mechanistic understanding (2023–2025 synthesis)

6.2 Expert interpretations / authoritative analyses

6.3 Suggested GO biological process terms (examples)

6.4 Suggested CL cell types and GO cellular components

7. Anatomical structures affected

7.1 Primary organs/systems

7.2 Suggested UBERON anatomical terms (examples)

8. Temporal development

8.1 Onset

8.2 Progression and triggers

9. Inheritance and population

9.1 Inheritance

9.2 Epidemiology

9.3 Population genetics / variant frequencies

10. Diagnostics

10.1 Clinical tests and evaluations used in practice

10.2 Genetic testing (recommended approach)

10.3 Differential diagnosis

11. Outcomes / prognosis

12. Treatment

12.1 Current real-world management